American Healthcare REIT, Inc. (NYSE: AHR) — Paying a Welltower Multiple for a Two-Year Track Record

Independent Equity Research Report date: 2026-07-11 · Price: $53.57 · Diluted shares ~190M · Market cap ~$10.2B · EV ~$10.4B · Net debt/EBITDA 3.0x Skeptical, evidence-driven fundamental analysis. The main body carries no recommendation and no price target — valuation is discussed only as embedded expectations and scenarios. The single, deliberate exception is the Claude's Take block immediately below.

⚡ Claude’s Take

This block is the author’s own subjective opinion. It is general information and independent commentary, not investment advice. Everything below it is the analysis proper and remains strictly recommendation-free and price-target-free.

Verdict: HOLD / great business, wrong entry — a quality compounder priced for perfection with no margin of safety. Not a short (the growth, the demographics, and the tape are all real); not a buy here. Accumulate only on a meaningful de-rating — roughly sub-$45 (~20x forward NFFO, ~2.2%+ yield). Conviction: medium.

Tag: “A Welltower multiple on a two-year operating record — and the insiders are selling into it.”

American Healthcare REIT is a genuinely good business that has done almost everything right since its February 2024 listing: it deleveraged a former non-traded retail REIT from mid-4x to a sector-low 3.0x net debt/EBITDA, bought in the last 24% of Trilogy (its crown-jewel, CON-protected integrated-campus platform) to reach 100% ownership, pruned the low-moat outpatient-medical and triple-net books, and rode the clearest demographic tailwind in real estate — the 80+ population inflection against record-low senior-housing supply — to nine straight quarters of double-digit same-store NOI and ~20% Normalized-FFO-per-share growth. The Trilogy core is a real moat (regulatory captivity via Certificate-of-Need, local integrated-campus scale, operator relationships) that shows up in the numbers: rising occupancy, rising rates, and net-negative competing supply. None of that is in dispute.

The problem is entirely price. At $53.57 the stock trades at ~24.5x forward and ~31x trailing NFFO, a ~1.9% dividend yield (frozen at $1.00 since Q1 2023), and the 98.9th percentile of its own price-to-sales history — the richest it has ever been on the one metric REIT accounting doesn’t distort — and it is priced right alongside Welltower, the larger, A-rated, longer-tracked premium name. You are paying a best-in-class multiple for a shorter public record, a majority-SNF/operating (structurally lower-multiple) book, a key-person overhang (CEO Prosky on open-ended medical leave since February 2026), and a growth algorithm that is reflexive: premium multiple → cheap forward equity → accretive ~7% deals → premium multiple. That flywheel is genuinely accretive today (issuing above NAV is unusual and favorable for a REIT) but inverts violently on any de-rate, just as sector cap rates are already compressing 25–50bps. The framing is momentum quality-compounder at a reflexive price — a low-volatility one-way-street-up (y1 +51%, Sharpe 2.0, ~2.7% off the high, crowded-long across Citi/Barclays/UBS), which the factor tape confirms with a negative Quality loading and real rate sensitivity. The loudest signal is insider behavior: with the stock up ~4x, the entire named insider group — CFO, general counsel, and the founder now serving as interim CEO — is selling into the all-time high, with zero open-market buys. When those closest to the numbers are monetizing the re-rating and the yield gives you a 1.9% cushion against a ~24x multiple, the risk/reward for a new buyer is poor even though the business is excellent.

Conviction: medium. Flips bullish if the stock de-rates ~20% (toward ~$45 / ~20x forward NFFO) while same-store NOI stays double-digit — i.e., you get the compounder without the reflexive premium — or if an insider steps in with a real open-market purchase. Flips bearish if same-store NOI decelerates below ~10% while the multiple stays above ~22x (a growth-multiple mismatch that de-rates hard), or if a SHOP labor / SNF-reimbursement shock compresses the operating-heavy book. The debate resolves on one variable: the durable same-store NOI growth rate once occupancy normalizes. Everything else is a derivative of that.

📈 Stock Price Action — Five-Year Event Map

Text-only by design — no chart is rendered. Price moves are FACT (AZI unadjusted close CSV); attributed drivers are INTERPRETATION, cross-referenced to earnings prints, 8-K events, guidance changes, and the news feed. No price target, no recommendation.

American Healthcare REIT has essentially one price story, and it points in one direction. From a February 2024 IPO reference of ~$13.22 (priced at $12), the stock ran to ~$28 by year-end 2024, ~$47 by year-end 2025, and printed an all-time high of $55.04 on July 2, 2026 before easing to $53.57 (July 10, 2026) — a near-monotonic ~4.0x in roughly 2.4 years. The 52-week range is $36.21–$55.04, leaving the stock ~2.7% off its record high and near the top of its entire (short) trading history. This is not a round-trip; it is a one-way re-rating of a formerly non-traded retail REIT into a premium-multiple institutional name, and the article’s valuation section assumes that context throughout.

Cycle narrative. (1) The February 2024 listing converted a non-traded, illiquid retail vehicle into a public REIT at a depressed reference price — the starting point for everything that followed. (2) Through 2024 the stock more than doubled as senior-housing occupancy recovered off COVID lows, the SHOP book swung to growth, the balance sheet began de-levering, and — the single most important portfolio event of the period — AHR bought in the last 24% of Trilogy for $258M in September 2024 to consolidate 100% of its highest-growth, highest-moat segment. This was a classic “the numbers are less scary than the price implied” re-rate. (3) The first half of 2025 extended the run on a cadence of quarterly NFFO beats and a portfolio simplification (selling outpatient medical and triple-net to concentrate into operating senior housing/care). (4) The second half of 2025 saw the guidance-raise machine continue and the now-100%-owned Trilogy NOI ramp, building the streak of double-digit same-store NOI quarters toward nine straight. (5) The 2026 leg is a sentiment-and-fundamentals combination: a 31.6% Q1 NFFO print, a raised full-year guide, 3.0x leverage, and a wave of sell-side upgrades (Citi to Buy, Barclays Overweight initiation, UBS Buy with a $63 target) that crowded the long. (6) The recent ~2.7% dip off the July 2 high carries no identified catalyst and is immaterial against the arc. The price moves are FACT; every attributed driver is INTERPRETATION, traceable to the earnings prints, the Trilogy 8-K, the guidance changes, and the news feed logged in the research log.

1. Executive Summary

American Healthcare REIT (NYSE: AHR) is a ~$10.4B-enterprise-value, self-managed diversified healthcare REIT that is, in economic substance, a senior-care operating company wearing a REIT wrapper. Roughly 72% of its NOI now flows through the RIDEA operating structure — the Trilogy integrated senior health campuses (57% of segment NOI) and the SHOP senior-housing book — with only a shrinking ~28% of contractual net-lease rent from outpatient medical and triple-net properties that management is actively selling. The portfolio spans 337 buildings/campuses and ~22.2M square feet across 36 states, the UK, and the Isle of Man, concentrated in the Midwest (Indiana 33% and Ohio 12% of NOI). AHR was assembled in 2021 from three non-traded Griffin-American vehicles and listed on the NYSE in February 2024 at $12; it has since risen ~4x to $53.57.

The business is genuinely good. It is riding the clearest structural tailwind in real estate — the 80+ population inflecting up ~55% by 2035 on a fixed biological clock, against senior-housing supply at a two-decade low because new construction does not pencil below replacement cost, and skilled-nursing beds in net-negative supply behind Certificate-of-Need barriers. The Trilogy core carries a real, financially-validated moat: CON regulatory captivity, integrated “age-in-place” campuses, a scarce bed-license bank, and a Medicare-Advantage quality-mix strategy (75.5% quality mix, SNF rate +5%/yr). Operating results are strong and organic: nine consecutive quarters of double-digit total-portfolio same-store NOI growth (+12.1% in Q1’26), Trilogy and SHOP NOI margins both crossing 20%, and Normalized FFO/share of $1.72 in 2025 (+22%) growing to a guided $2.09–$2.30 in 2026 (~+20%). The balance sheet is deliberately conservative — net debt/EBITDA of 3.0x, effectively all fixed-rate, with an undrawn $800M revolver.

The debate is entirely about price and durability. At $53.57, AHR trades at ~24.5x forward and ~31x trailing NFFO, a 1.9% dividend yield (frozen since Q1 2023), and the 98.9th percentile of its own price-to-sales history — priced alongside Welltower despite a shorter record, a lower-multiple operating/SNF-weighted mix, and a key-person overhang (CEO Prosky on medical leave since February 2026; founder Hanson interim). The growth is partly a reflexive equity-issuance flywheel (premium multiple funds accretive ~7% deals, which supports the multiple) that inverts on a de-rate — precisely as sector cap rates compress. Two lower-quality contributors flatter the headline: a cyclical SHOP lease-up recovery that must decelerate, and accretive issuance that depends on the premium persisting. Insiders — CFO, general counsel, and the interim-CEO founder — are uniformly selling into the all-time high, with zero open-market buys.

Embedded expectations. At ~24.5x forward NFFO with a ~1.9% yield, the market is underwriting years of mid-teens-to-20% NFFO compounding and durable retention of a top-of-sector multiple and an uninterrupted accretive-issuance engine — three assumptions that must all hold, with only a thin yield to cushion a disappointment in any one. The demographic tailwind, occupancy runway, and low leverage are being priced correctly; perpetual 20% growth, zero multiple mean-reversion, and no capital-cycle response likely are not. Most of the easy ~4x re-rating is behind the stock, not ahead of it. This article takes no position and sets no price target; the sole opinion is the labeled Claude's Take above.

2. Business Overview

American Healthcare REIT, Inc. (NYSE: AHR) is a self-managed, internally-managed diversified healthcare REIT headquartered in Irvine, California, that owns and operates a portfolio of clinical healthcare real estate concentrated in senior housing, skilled nursing, and outpatient medical property (Fact — 2025 10-K, Item 1, filed 2026-02-27). As of December 31, 2025 it owned and/or operated 337 buildings and integrated campuses totaling ~22.2 million square feet of gross leasable area, at an aggregate contract purchase price of ~$5.42 billion, across 36 U.S. states, the United Kingdom, and the Isle of Man, run by an internal platform of ~121 employees (Fact — 10-K, Item 1 & Item 2).

The defining structural fact about AHR is that it is not primarily a landlord — it is, increasingly, an operator of healthcare businesses that happens to own the underlying real estate. Roughly three-quarters of its economics now flow through a RIDEA (REIT Investment Diversification and Empowerment Act of 2007) structure, in which the REIT, through a taxable REIT subsidiary (TRS), captures the operating profit-and-loss of the facility — resident fees, labor, food, insurance, reimbursement — rather than collecting a contractual rent check. This is the single most important lens for the entire memo: AHR consolidates ~$2.3 billion of operator-level revenue (Fact — FY25 revenue $2.26B, ROIC/10-K) at a ~17–18% EBITDA margin, versus the 90%+ NOI margins of a pure net-lease REIT. The headline “revenue” and “margin” are therefore not comparable to Realty Income or a triple-net peer; the correct comparison set is Welltower’s and Ventas’s SHOP/operating books.

The four segments — and the direction of travel

The 10-K reports four operating/reportable segments. The segment mix, measured by annualized base rent / NOI, is (Fact — 10-K, Item 2 real-estate table, as of 12/31/25):

Two blocs, moving in opposite directions:

• The RIDEA operating bloc — ISHC (Trilogy) + SHOP = ~74% of NOI and growing. This is where AHR is deploying every incremental dollar. Year-to-date 2026 acquisitions were 100% SHOP (~$249M), the awarded pipeline is $650M+ “mostly SHOP,” and Trilogy is being expanded through ground-up development (Fact — Q1’26 transcript, 2026-05-08).
• ISHC / “Trilogy” (55.5% of NOI, the crown jewel). 147 integrated senior health campuses that co-locate independent living, assisted living, memory care, and skilled nursing “under one roof,” allowing residents to “age-in-place” as their acuity rises (Fact — 10-K). These are need-driven, market-rent (not entry-fee) campuses concentrated in the Midwest — Indiana alone is 33.4% and Ohio 11.5% of total portfolio annualized rent/NOI (Fact — 10-K, geographic concentration). Trilogy is operated by Trilogy Management Services; in Q3 2025 AHR bought the remaining 24% of Trilogy REIT Holdings it did not own for $258M cash, taking it to 100% ownership (Fact — log/10-K). This consolidation is the pivotal capital-allocation event of the last two years — AHR chose to lever into the operating-intensive campus business rather than diversify away from it.
• SHOP (18.7% of NOI). 97 senior-housing communities (assisted living / memory care / independent living) run under RIDEA with third-party operators. This is the fastest-growing segment by design, but — as argued — it is the thinnest business AHR owns.
• The net-lease bloc — OM + Triple-Net = ~26% of NOI and shrinking. Management is a net seller here: it has disposed of more than a third of the outpatient-medical book and is running off the triple-net portfolio, redeploying proceeds into SHOP/Trilogy (Fact — log; Q1’26 transcript). OM (74 buildings) is classic medical-office — specialized physician-office space, largely on/near hospital campuses, on contractual net leases; triple-net (19 properties, 100% leased) is the last remnant of the legacy net-lease model. Management frames OM as “stable and reliable cash flow… particularly valuable during market disruptions” (Fact — 10-K), i.e., ballast it is willing to trade for growth.

RIDEA vs. net-lease economics — why this matters

Under a triple-net lease, the tenant bears operating risk and the REIT collects a fixed, escalating rent (bond-like, ~90%+ margin, but no upside from improving operations). Under RIDEA, AHR — through its TRS — “bears operational risks and liabilities associated with the operation of such healthcare facilities,” including “resident quality-of-care claims and governmental reimbursement matters” (Fact — 10-K). In exchange, it “participate[s] in the upside from any improved operational performance while bearing the risk of any decline.” (Interpretation) This is the double-edged core of the AHR thesis: the same structure delivering the 9-consecutive-quarters of double-digit same-store NOI growth is a low-margin, labor-heavy, reimbursement-exposed operating business that would cut the other way in a downturn — margin compression, occupancy loss, and wage inflation would hit NOI directly, unbuffered by a lease. AHR has converted itself from a landlord into a healthcare operator with a real-estate balance sheet.

Recurring vs. operating revenue

There is very little “contractual, recurring rent” left in the model. Only the ~26% net-lease bloc (OM + triple-net) produces lease-like recurring revenue with embedded escalators; the ~74% RIDEA bloc produces operating revenue — resident fees and services that must be re-earned every month at prevailing occupancy, rate, and cost structure. Revenue is “recurring” in the demographic sense (residents need care) but not in the contractual sense (there is no lease locking in the cash flow). This is a materially lower-quality revenue base than a net-lease REIT’s, and analysts who apply a net-lease mental model to AHR’s “revenue growth” are mis-framing the business. (Interpretation)

The Griffin-American non-traded → listed history

AHR’s provenance shapes its governance and share-count profile. It was formed in 2021 via a tri-party merger of three non-traded vehicles: Griffin-American Healthcare REIT III, Griffin-American Healthcare REIT IV, and American Healthcare Investors — the external manager, which was internalized in the deal, making AHR self-managed (Fact — log/S-11 history). It then IPO’d on the NYSE on February 7, 2024 at $12/share (Fact). In other words, AHR spent most of its life as a non-traded retail REIT — the product category historically associated with high load fees, illiquidity, and NAV opacity — before its 2024 listing. Two consequences: (1) the founder/sponsor lineage is still in the chair — Jeffrey T. Hanson (Chairman, founder of the predecessor Griffin-American entities) stepped in as Interim CEO in February 2026 when CEO Danny Prosky went on medical leave (Fact — log; a key-person/governance overhang, though continuity is preserved via the founder); and (2) the share count has ballooned — average diluted shares went from ~66M (FY22–23) to ~131M (FY24) to ~166M (FY25), roughly 2.5x dilution in three years — but, critically, most of it was issued at rising post-IPO prices well above prior NAV, making it accretive rather than value-destructive (Interpretation —/).

Verdict — Business Overview: AHR is a healthcare operator wearing a REIT’s clothing. The economics are ~74% RIDEA operating income (Trilogy + SHOP) and only ~26% contractual net-lease rent, and management is deliberately widening that ratio — buying SHOP, running off OM/triple-net, and consolidating Trilogy to 100%. That mix concentrates AHR into the highest-growth and highest-operating-risk corner of healthcare real estate, anchored by a genuinely differentiated Midwest campus platform (Trilogy) and a more commoditized SHOP book. The business is well-positioned demographically but structurally lower-margin, more reimbursement-exposed, and less contractually durable than a net-lease REIT — a fact the 74%-RIDEA mix makes non-negotiable, and one the market’s premium multiple appears to under-weight.

3. Industry Dynamics

AHR operates in three distinct sub-industries with different structures: senior housing (private-pay assisted living / memory care / independent living — the SHOP and part of the ISHC book), skilled nursing (SNF — the acute, reimbursement-driven core of Trilogy), and outpatient medical (MOB — the shrinking net-lease bloc). The bull case rests overwhelmingly on the first two.

Demand: the clearest demographic tailwind in real estate

The demand side is not seriously disputable. The U.S. population aged 80+ — the prime entry cohort for assisted living, memory care and skilled nursing — is ~14.7M in 2025 and is projected to reach ~23M by 2035, a ~55%+ increase, with ~28% growth by 2030 alone (Fact — NIC MAP; U.S. Census projections, per prior WELL work, 2026-06). The oldest baby boomers turn 80 in 2026 — the demand cohort is only now beginning to arrive, and it ages on a fixed biological clock. Unlike most “TAM” narratives, the customer already exists; demand visibility through ~2035 is unusually high. This is the identical structural thesis underpinning Welltower and Ventas, and it is real. (Fact/Interpretation)

Supply: a genuine, quantified below-replacement-cost constraint

The supply side is the strongest single fact in the industry. In the NIC primary markets, senior-housing inventory growth ran ~0.4% year-over-year in early 2026 — the lowest on record back to 2006 (Fact — NIC MAP). Construction starts are near their lowest since ~2009; the development cycle has stretched to ~29 months, so anything breaking ground now does not open until 2027–2028; and NIC estimates the U.S. needs ~549,000 additional units by 2028 (and ~806,000 by 2030) merely to hold current penetration, against deliveries tracking roughly a third of requirement (Fact — NIC MAP). Capital fled the sector during COVID (operators failed, lenders retreated), which is precisely why supply collapsed. AHR management corroborates from the ground: new senior-housing construction “doesn’t pencil below replacement cost,” and it is buying stabilized assets at “yields in the 7s… below replacement cost” (Fact — Q1’26 transcript). On the SNF side the constraint is even tighter — Trilogy notes SNF beds are in net-negative supply (more beds going offline than coming online), reinforced by Certificate-of-Need regulation (below). (Fact/Interpretation)

Skilled nursing: CON regulation and reimbursement

Skilled nursing is structurally different from private-pay senior housing — it is a regulated, reimbursement-driven business and is the acuity core of Trilogy. Two features define it:

• Certificate of Need (CON). In many of Trilogy’s states, adding SNF beds/units or changing ownership requires state CON approval; “CON laws and regulations may place restrictions on… the addition of beds/units at our facilities and changes in ownership” (Fact — 10-K). CON is a government-granted barrier to entry: it caps supply in a given market regardless of demand, which both protects incumbents’ occupancy/pricing and creates value in an existing “bed-license bank.” This is the regulatory backbone of the Trilogy moat.
• Reimbursement mix. SNF revenue is a blend of Medicare / Medicare Advantage (MA), Medicaid, and private pay. The profitable segments are Medicare/MA and private pay; Medicaid typically reimburses at or below cost. Trilogy’s edge is its “quality mix” of 75.5% — the share of revenue from the higher-paying payors — up 60bps year-over-year, with SNF rate +5%/yr and MA rate +6.6% last quarter (Fact — Q1’26 transcript). CMS’s preliminary FY-rate update of ~2.4% for SNF (Fact — task/CMS) is a modest but positive tailwind. The risk cuts both ways: reimbursement is a policy variable — a Medicaid squeeze, an MA rate reset, or a change in the value-based-care landscape would hit Trilogy’s NOI directly, with no lease to absorb it. (Interpretation)

Outpatient medical: the ballast AHR is selling

MOB is the most bond-like healthcare property type — creditworthy health-system and physician tenants, long net leases, on/near hospital campuses with real (if modest) switching costs, secular demand from the inpatient-to-ambulatory shift, and same-store NOI in the low-single digits (Fact — cf. Healthpeak public disclosure, MOB same-store ~+2–5%). It is a good, stable business — which is exactly why AHR’s decision to sell it (>1/3 disposed) is a considered trade of stability for growth, not a distress sale. (Interpretation)

Marathon capital-cycle read: favorable on supply, late-stage on capital

Applying the Marathon “Capital Returns” lens (supply-side capital-cycle analysis): senior housing is a textbook favorable setup on the physical supply axis — high visible incremental returns, collapsed new construction, demand accelerating on a fixed clock. But the framework’s warning is on the capital axis, and here the signal is turning. Transaction volume has surged toward decade highs, institutional investors are re-allocating heavily into the sector (e.g., Kayne Anderson’s largest-ever senior-housing-targeted fund), and — per AHR’s own commentary — cap rates have compressed ~25–50bps and “more players are entering” (Fact — Q1’26 transcript; NIC/trade press). High returns are attracting capital, exactly as the capital cycle predicts. The physical-supply window stays open through ~2027–2028 (you cannot un-collapse a construction pipeline overnight), but the return window on new acquisitions is already narrowing. AHR is thus late-cycle on the axis — capital inflows — that determines the accretion on its forward pipeline, even while early-cycle on the axis — physical supply — that determines organic same-store growth. (Interpretation)

Verdict — Industry: structurally GOOD, with a late-cycle capital caveat. The demand tailwind (80+ +55% to 2035) is locked in on a biological clock; the supply constraint (inventory growth at a two-decade low, construction below replacement cost, SNF beds net-negative, CON caps in many states) is genuine and quantified. This is a demonstrably favorable industry — the same one WELL and VTR are riding — and reimbursement risk is concentrated in the SNF/Trilogy slice rather than the private-pay majority. The single qualifier is Marathon’s other half: capital is now rushing back in, compressing acquisition cap rates and narrowing the accretion on AHR’s $650M forward pipeline. Good industry; the debate is who captures the economics, how durably, and at what equity price.

4. Competitive Position

AHR’s moat question splits cleanly along its own segment line: SHOP has essentially no moat; Trilogy has a real, if bounded, one. Because Trilogy is 55.5% of NOI and SHOP is 18.7%, the honest answer is that AHR is majority a differentiated business with a large commoditized wing — not a uniformly moaty franchise, and not a uniformly commoditized one.

SHOP: a thin, replicable, labor-exposed operating business

Strip the demographic story away and a SHOP community is a local operating business — a building full of seniors, run by a third-party operator, where ~60% of the cost base is labor (Fact — industry norm, cf. Welltower public disclosure). There is no structural barrier to a competitor building or buying an identical community across the street (outside CON, which does not bind private-pay assisted living the way it binds SNF). In Greenwald’s taxonomy, SHOP has no genuine competitive advantage: no supply/cost advantage (operators are largely interchangeable and inputs — labor, food, insurance — are market-priced), no meaningful demand-side captivity (residents are sticky once placed — relocating a frail senior is disruptive — but there is no lock-in at the point of choice, and choice is local and price/quality-driven), and no network effect (a community in Arizona confers zero value on a resident in Wisconsin — the same “network effect” claim WELL makes and that should be discounted there too). What SHOP has is a cyclical tailwind — record-low supply plus a demand wave producing outsized lease-up economics — which is not a moat; it is a favorable moment that new capital is, by the capital-cycle logic of, actively competing away. The test: if you removed AHR’s SHOP “advantage,” what financial outcome would deteriorate? Very little that a well-run peer operator could not replicate — which is the definition of no moat. (Interpretation) This matters because SHOP is the segment AHR is buying most aggressively (100% of YTD acquisitions), i.e., it is deploying the most capital into the least defensible business, at cap rates being compressed by the very capital inflows the sector is attracting.

Trilogy: a genuine local-scale + regulatory-captivity moat

Trilogy is a different animal, and management’s claim that it is “the most durable competitive moat in our entire portfolio” is defensible on the evidence. The mechanism is a stack of three real advantages that reinforce each other:

1. Regulatory captivity via CON (a government-granted barrier to entry). Trilogy is concentrated in Midwest CON states (Indiana 33.4%, Ohio 11.5% of NOI). In a CON state, a competitor cannot add competing SNF beds without state approval — supply is legally capped. Trilogy’s accumulated “bed-license bank” (the stock of licensed beds it controls across its markets) is therefore a genuinely scarce, non-replicable asset: a new entrant cannot simply out-build it. The financial test passes: without CON captivity, competing supply would enter Trilogy’s markets, pressuring the 91.2% occupancy and the +5%/yr SNF rate; the fact that SNF supply is net-negative while occupancy and rate both rise is the moat showing up in the numbers. (Interpretation, grounded in 10-K CON language + Q1’26 occupancy/rate facts.)
2. The integrated “age-in-place” campus (local-scale economies + demand captivity). ~75% purpose-built campuses that co-locate IL/AL/memory-care/SNF let a resident escalate acuity without leaving the campus — a genuine switching-cost/captivity dynamic that a stand-alone assisted-living community cannot match, and that is hard to replicate because it requires assembling all license types and physical infrastructure in one location (which CON makes harder still). This is Greenwald’s rare “economies-of-scale + captivity” combination operating at the local market level — the only level at which senior-care scale actually confers advantage. (Interpretation)
3. Operator relationships, density, and dynamic-pricing technology (intangibles). Consolidating Trilogy to 100% internalized the operating platform; regional density creates real cost synergies (shared labor pools, procurement, management overhead), and Trilogy runs a proprietary dynamic-pricing system and MA-selectivity strategy that drives the 75.5% quality mix and +6.6% MA rate. These are legitimate intangible advantages — but they are the weakest leg (replicable with time and capital by a determined, scaled operator) and should be weighted least. (Interpretation)

The Trilogy moat is local, not national — it does not travel to arbitrary geographies (which is exactly why Trilogy expansion is constrained to contiguous Midwest CON markets, ). But within its markets it is real, and it shows up financially: rising occupancy + rising rate + net-negative competing supply + expanding NOI margin (>20% first time since COVID) is what a working moat looks like. (Interpretation)

Direct comparison vs. peers

• vs. Welltower (WELL): WELL is the premium SHOP compounder — larger, A-rated, ~14 straight quarters of 20%+ SHOP NOI growth, ~25–30 near-exclusive operator partnerships. On the SHOP game, WELL is bigger, better-capitalized, and further along the operating-platform curve; AHR is a smaller follower. But AHR’s differentiator is Trilogy — an integrated-campus + CON-SNF franchise WELL largely does not have. AHR’s moat is narrower geographically but deeper regulatorily (CON) than WELL’s scale-and-relationships moat.
• vs. Ventas (VTR): VTR is likewise SHOP-and-scale-driven, trying to widen a relationship/data moat similar to WELL’s. Neither VTR nor WELL has AHR’s Midwest integrated-SNF-campus concentration; conversely AHR lacks their scale, credit rating, and capital cost.
• vs. pure-SNF / pure-SHOP operators (e.g., Ensign/CareTrust-type SNF, standalone AL operators): Pure SNF operators (like ENSG) capture the CON/reimbursement advantage but lack the private-pay senior-housing upside and the campus continuum; pure-SHOP names capture the demographic wave but have no regulatory captivity at all. AHR’s Trilogy uniquely combines private-pay senior housing with CON-protected SNF in one campus — that combination is its genuine point of differentiation.

Verdict — Competitive Position: a genuinely-moaty majority (Trilogy) attached to a commoditized, capital-hungry wing (SHOP). Trilogy (55.5% of NOI) has a real, financially-validated moat — CON regulatory captivity + local integrated-campus scale + operator/pricing intangibles — that shows up as rising occupancy, rising rates, and net-negative competing supply; remove it and the economics measurably deteriorate, which is the moat test passing. SHOP (18.7%) has no moat — it is a thin, replicable, labor-exposed operating business enjoying a cyclical tailwind that new capital is competing away, and it is precisely where AHR is deploying the most capital. Net: AHR is not a uniformly wide-moat compounder; it is a differentiated Midwest campus operator (defensible) bolted to a me-too senior-housing roll-up (not). The durable advantage is real but bounded and local, and the segment AHR is growing fastest is the one that lacks it. Durable advantage in the core, crowded market at the margin.

5. Growth History and Forward Opportunities

The history: real, accelerating, and largely organic

AHR’s growth record since listing is genuinely strong on every operating metric:

• Revenue: FY22 $1.62B → FY23 $1.86B → FY24 $2.07B → FY25 $2.26B → TTM (Q1’26) ~$2.37B — roughly +10–14%/yr (Fact — ROIC/10-K).
• Normalized FFO: FY25 NFFO of $286.5M, +55% YoY (FY24 $184.9M); NFFO/share ~$1.73 in 2025 (Fact — 10-K FFO reconciliation).
• Same-store NOI: Total-portfolio same-store NOI grew +12.1% in Q1’26 — the ninth consecutive quarter of double-digit same-store NOI growth (Fact — Q1’26 transcript). This is the core of the story and it is overwhelmingly organic.
• Trilogy/ISHC SS NOI +14.5%, occupancy 91.2% (+~220bps YoY), quality mix 75.5% (+60bps), SNF rate +5%/yr, NOI margin above 20% for the first time since COVID (+134bps in 2025).
• SHOP SS NOI +19.7%, occupancy 88.6% (+~255bps YoY), NOI margin 20.6% (+215bps).
• NFFO/share Q1’26 $0.50, +31.6% YoY (Fact — transcript).

The quality of this growth is high on the organic axis and comes from three durable-looking levers: (1) occupancy runway — both books are still in the high-80s/low-90s with a clear path toward >90–95%, and incremental residents flow through at very high margins because communities are already largely staffed (operating leverage); (2) rate + quality-mix — Trilogy’s dynamic pricing, MA selectivity (+6.6% MA rate), and +5%/yr SNF rate lift revenue independent of occupancy; and (3) margin expansion — NOI margins crossing 20% as wage inflation moderates and occupancy leverages fixed costs. None of this is financial engineering — it is operating improvement in a supply-constrained, demand-rich market. (Fact/Interpretation)

The forward opportunity set

• Organic (the durable core). 2026 guidance raises same-store NOI growth to 9–12% (Trilogy 11–15%, SHOP 15–19%, OM 0–2%, triple-net 2–3%) and NFFO/share to $2.09–$2.30 (mid ~$2.19, +20% over 2025) (Fact — Q1’26 transcript). The occupancy runway alone (Trilogy 91.2%, SHOP 88.6% vs. a >90–95% stabilized target) plus rate/mix supports several more years of above-average same-store growth if the demographic/supply backdrop holds.
• Acquired (the reflexive engine). YTD $249.2M of acquisitions (100% SHOP, all with existing operators — a risk-reducing choice) and a $650M+ awarded pipeline (mostly SHOP, ~80% existing operators, expected to close by Q3) at stabilized yields “in the 7s,” below replacement cost (Fact — transcript). This external growth is funded by equity — ATM forward sales of 8.1M shares / $412.7M plus $527.4M of unsettled forwards, >$1B available, against a deliberately low 3.0x net-debt/EBITDA run toward IG ratios (Fact — transcript). Crucially, the equity is issued at a premium multiple (rich P/NFFO, richest-ever P/S), so it is accretive — but this is a reflexive flywheel (premium multiple → cheap equity → accretive deals → sustained multiple) that works only while the multiple stays elevated. It is not a self-funding compounding machine; it is cycle-timing plus accretive issuance, and it reverses if the multiple compresses or acquisition cap rates keep falling (as 's capital cycle warns).
• Development (the highest-return, most-constrained lever). $173.9M of Trilogy campus expansions / independent-living “villas” ($52.4M funded), building at below-replacement cost into the existing bed-license bank (Fact — transcript). Development yields exceed acquisition yields but are geographically constrained — Trilogy expansion is confined to contiguous Midwest CON markets (Wisconsin/Indiana), because the moat (CON, density, operator relationships) does not travel. That constraint is the flip side of the moat: what makes Trilogy defensible also caps how fast it can scale.

Quality of growth: durable compounding, or cycle-timing + reflexivity?

The honest read is both, in different segments. Trilogy’s organic growth is the closest thing to durable compounding — moat-protected, occupancy-and-rate-driven, into a structurally supply-constrained market. SHOP’s growth is higher-percentage but lower-quality: it is (a) a cyclical lease-up recovery that must mathematically decelerate as occupancy fills (the same post-COVID catch-up caveat that applies to WELL/VTR — a 19.7% SHOP NOI rate cannot annualize forever), and (b) acquired growth dependent on the equity-issuance flywheel and on acquisition cap rates that capital inflows are compressing. The 2026 guide implicitly assumes the flywheel keeps spinning and same-store stays double-digit; both are reasonable near-term but neither is guaranteed medium-term. (Interpretation)

Verdict — Growth quality: high-quality in the Trilogy core, medium-quality at the SHOP/acquired margin. The organic engine — nine straight quarters of double-digit same-store NOI, a genuine occupancy runway to >90%, rate and quality-mix gains, and expanding margins into a supply-starved market — is real, durable-looking, and moat-underpinned in Trilogy. But the headline growth rate is flattered by two lower-quality contributors: a cyclical SHOP lease-up recovery that must decelerate, and an accretive-issuance flywheel that depends on the premium multiple persisting and on acquisition spreads that the sector’s capital inflows are actively narrowing. This is not free-cash-flow-funded self-compounding; it is strong organic growth plus reflexive equity-funded external growth. The durable core justifies calling the growth high-quality; the market’s premium multiple prices the entire growth stack — including its most reflexive, most decelerating parts — as if it were the durable core.

6. Financial Quality

6.1 Revenue growth and composition — a consolidated operator, not a landlord

FACT. Total revenue: FY22 $1.62B → FY23 $1.86B → FY24 $2.07B → FY25 $2.26B → TTM Q1’26 ≈ $2.37B (≈ +9–14%/yr). The critical structural point: ~85% of that “revenue” is resident fees and services collected under the RIDEA structure at the Integrated Senior Health Campuses (ISHC / “Trilogy”) and SHOP segments — i.e., AHR consolidates the gross operating revenue and the gross operating cost of running senior-care communities. This is not rental income. It is why the income statement carries an ISHC compensation-expense line of $901.8M and controllable operating expenses of $552.7M in FY25 (10-K segment footnote). AHR is, in economic substance, a ~$2.3B senior-care operating company wearing a REIT wrapper on ~45% of its assets, plus a shrinking triple-net/outpatient landlord on the rest.

Segment NOI (10-K segment footnote; $000):

INTERPRETATION. The portfolio is being deliberately rotated into the two operating (RIDEA) segments and out of the two contractual-rent segments. Trilogy went from 50% of segment NOI (FY23) to 57% (FY25); the 10-K risk factors state ISHC contributes ~55.5% of annualized NOI on 45.3% of portfolio contract value. SHOP tripled (FY23 $20.4M → FY25 $64.0M). Meanwhile OM fell from $91.6M to $77.4M (>1/3 of the OM book sold) and triple-net from $49.8M (FY24) to $36.8M (FY25). By FY25, ~72% of NOI is operating/RIDEA (ISHC + SHOP) and rising — this is the single most important fact about AHR’s earnings quality: it is more cyclical, more labor-exposed, and lower-margin than a net-lease healthcare REIT, and moving further that way by design.

6.2 Why the ~17% EBITDA margin is not a red flag but also not comparable

FACT/INTERPRETATION. Consolidated EBITDA margin runs ~17–18% and is roughly flat, versus 90%+ for a triple-net REIT (e.g., an Omega or the NNN sleeve of Ventas). This is a RIDEA gross-up artifact, not operational weakness: total segment NOI of $415.2M on $2.26B revenue = an 18.4% blended property margin because the P&L includes ~$1.5B of pass-through care-delivery cost. The right margin lens is segment NOI margin, and there the story is genuinely improving: SHOP NOI margin reached 20.6% in Q1’26 (+215bps YoY) and Trilogy crossed >20% for the first time since COVID (+134bps in 2025) (Q1’26 transcript). Do not compare AHR’s headline margin cross-sectionally to net-lease peers — it is an apples-to-oranges error the AZI P/S percentile (98.9, richest-ever) partly reflects.

6.3 The GAAP → FFO → NFFO bridge (GAAP EPS is not the earnings metric)

FACT. GAAP net income to common: FY22 –$81M, FY23 –$71M, FY24 –$38M, FY25 +$70M (first GAAP-profitable year, ~+$0.42 diluted); Q1’26 net income $24.0M vs –$6.8M in Q1’25. GAAP finally turned positive mostly because (i) real-estate D&A is now spread over a far larger share count and (ii) interest expense fell after the IPO/offering-funded deleveraging — not because the assets suddenly earn their depreciation charge back. The dominant reconciling item is depreciation & amortization: $67.1M in Q1’26 alone (~$268M+ annualized), growing with the asset base — larger than net income by a wide margin. For a real-estate operator this D&A is a non-economic charge (buildings do not actually lose value on a 30–40yr straight line while occupancy and rates rise), so GAAP EPS materially understates cash earnings. Use FFO/NFFO.

FY2025 FFO → Normalized FFO bridge (10-K MD&A; $000):

NFFO $286.5M FY25 = +55.0% YoY. Per-share NFFO: $1.72 (2025) vs $1.41 (2024), +22% (proxy confirms $1.72/$1.41); per-share lags the aggregate because of the share-count ramp. Q1’26 NFFO $94.8M / 187.97M diluted shares = $0.50 (+31.6% vs $0.38). 2026 guidance $2.09–$2.30, midpoint ~$2.19 (+~20% over 2025’s $1.83 run-rate implied by guide).

Quality-of-earnings read on the bridge (INTERPRETATION):

• Positive/conservative: AHR removes the $23.7M non-cash income-tax benefit (the reversal of TRS valuation allowances) from NFFO — the single largest adjustment, and it cuts against the company. That is the honest direction. It also strips the $14.6M Trilogy re-measurement gain and FX. NFFO is below NAREIT FFO ($286.5M < $293.3M), the correct sign for a clean operator.
• Watch item: the +$14.6M add-back of “non-cash changes to equity instruments” (stock-based comp) flatters NFFO. SBC is a real, recurring economic cost (dilution), and it is rising (FY24 $9.4M → FY25 $14.6M) as the stock re-rates and as the new operator-incentive plan grants begin. Backing it out is standard REIT practice but investors should mentally deduct ~$0.09/sh of SBC to get to a true cash figure.

6.4 AFFO / maintenance capex — a disclosure gap

FACT. AHR does not disclose AFFO (zero mentions in the 10-Q; the 10-K uses “AFFO” only in generic passages). For an operating-intensive senior-care REIT this is a real gap, because recurring maintenance capex is material and NFFO does not deduct it. Extractable proxy: the 10-K guides ~$91.8M of capital and tenant-improvement spend for 2026 on a ~$5.4B portfolio, and holds $12.1M of restricted cash in capex/impound reserves. If one treats even ~$60–70M of that as recurring/maintenance (the balance being revenue-enhancing campus expansions/villas), estimated AFFO would sit meaningfully below NFFO — roughly $1.35–$1.45/sh vs $1.72 NFFO for 2025. OPEN QUESTION for diligence: management should be pressed to publish an AFFO/maintenance-capex reconciliation; its absence makes the ~24x forward NFFO multiple look optically cheaper than a like-for-like AFFO multiple would.

6.5 Chronic impairments — a standing earnings-quality flag

FACT (corrected). Real-estate impairments recur every year: FY22 ~$78M; FY23 $13.9M (the log’s “$24M” is wrong — the 10-K states $13,899K); FY24 $45.8M ($45,755K); FY25 $49.9M ($49,935K, on eight OM buildings + one SHOP). INTERPRETATION. These are excluded from FFO (per NAREIT), so they don’t hit the headline metric — but four straight years of write-downs totaling ~$188M is a tell that (a) chunks of the legacy non-traded-REIT portfolio (especially OM) were carried above realizable value, and (b) the “growth” narrative is partly a portfolio being marked down and sold at losses even as the crown-jewel Trilogy compounds. FY25’s impairments were almost entirely OM buildings being exited — i.e., the pruning is being done at a loss to book. Not thesis-breaking, but it belittles GAAP book value and reinforces why book-based returns are meaningless here.

6.6 ROE / ROIC — why book-based returns are the wrong tool

INTERPRETATION (methodology). Book ROE/ROIC is not meaningful for AHR: (i) real estate is carried at depreciated historical cost (37 years of a former non-traded REIT’s cost basis, net of ~$188M of impairments), which understates true asset value; (ii) the giant, non-economic D&A charge depresses the numerator; (iii) the denominator (book equity) is distorted by the $1.5B of dilutive equity raised near-book. Any “ROIC ≈ X%” derived from GAAP will read artificially low and tell you nothing about unit economics. Correct lens: NOI yield / cash-on-cost. Newly acquired SHOP stabilizes at yields “in the 7s” (Q1’26 transcript), development/Trilogy villa expansions higher; same-store NOI is compounding +12.1% (Q1’26, ninth straight double-digit quarter) on a low-single-digit revenue base — an unlevered cash-on-cost trajectory that is genuinely strong. The economics are real; they simply do not show up in GAAP returns.

6.7 Balance sheet — deliberately de-levered, effectively all fixed-rate

FACT (YE2025, 10-K Notes 7–8 + MD&A):

• Fixed-rate mortgage loans: $985.6M across 85 loans, effective rates 2.21%–5.99%, wtd-avg 3.73%.
• 2024 Credit Facility: $1.15B capacity ($600M senior unsecured revolver + $550M senior unsecured term loan). $550M drawn (the term loan) at 5.01%; ~$650M available. Term loan matures Jan 19, 2027 (near-term refi item); revolver matures Feb 14, 2028 (one 12-mo extension option).
• All-in weighted-average effective rate 4.34% after interest-rate swaps.
• Effectively zero floating-rate exposure: the 10-K states a +0.50% rate move would have “no impact” because all variable-rate balances are swapped to fixed. Debt is ~64% secured mortgages / ~36% unsecured facility, but rate-risk is neutralized.
• Debt is largely non-recourse at the property level (mortgage subsidiaries), except the $550M 2024 Credit Facility, which AHR guarantees.
• Held-to-maturity CMBS debt security investment $92.1M @ 4.24% (a legacy asset, collateralized by senior-housing properties AHR partly controls).

Leverage: total debt ~$1.54B (YE25). Net debt/EBITDA improved to 3.0x at Q1’26 (from 3.4x YE25) — genuinely low for a healthcare REIT and run there deliberately (mgmt: helps the equity “trade at the best multiple,” Q1’26 call). Revolver undrawn/mostly available; $537.6M of unsettled forward-equity sits as dry powder. Liquidity is not a concern; the near-term item is the Jan-2027 term-loan maturity, refinanceable given IG-like metrics.

6.8 Verdict — do economics improve with scale?

Yes at the property level; conditionally at the corporate level. The genuine operating leverage is occupancy-driven: SHOP same-store occupancy 88.6% (+255bps) and Trilogy 91.2% (+220bps) are still well below the mid-90s stabilized ceiling, and because the cost base is largely fixed (staffing, real estate), incremental revenue from filling units drops through at very high incremental margins — hence same-store NOI compounding +12–20% on +6–7% same-store revenue, and NOI margins climbing 130–215bps/yr. That is real, and it has room to run as the 80+ population inflects. But the corporate model does not self-fund that growth: NFFO/sh grows only because the external equity raised is deployed at yields (~7%) above the cost of that equity — a genuine but reflexive advantage. Property economics improve with scale; shareholder economics improve with scale only while the premium multiple persists. Earnings quality is above-average for the operating-REIT cohort (clean NFFO bridge, low leverage) but structurally below a net-lease REIT (cyclical, labor-exposed, chronic impairments, no AFFO disclosure).

7. Capital Allocation

7.1 Use of IPO / offering proceeds — deleveraging first, then growth

FACT. AHR listed on the NYSE Feb 7, 2024 (priced $12) after ~decade as a non-traded retail REIT. The first use of IPO and 2024 follow-on proceeds was deleveraging: the 10-K states net proceeds since Feb 2024 were used to “pay off all variable-rate mortgage loans payable and pay down variable-rate lines of credit,” cutting interest expense by ~$31.8M in FY25 and taking net debt/EBITDA from mid-4x to 3.0x. INTERPRETATION: this was the correct sequencing — a former non-traded REIT arrived over-levered and rate-exposed; management fixed the balance sheet before leaning into acquisitions. Credit for discipline here.

7.2 The Trilogy 24% buyout — the best capital-allocation decision (Sept 2024, not 2025)

FACT. On September 20, 2024 AHR bought the remaining 24.0% minority stake in Trilogy REIT Holdings from a NorthStar Healthcare (NHI) subsidiary for $258.0M all-cash ($247.0M base + $11.0M distribution true-up), funded by the September 2024 equity offering; AHR now owns 100% of Trilogy (10-K, Note 10). INTERPRETATION: unambiguously value-accretive. Trilogy is the highest-growth, highest-quality, most-moated asset in the portfolio (CON-protected SNF supply, integrated campuses, >20% and rising NOI margins). Buying in the minority captures 100% of the segment that has since driven ISHC NOI from $189.3M (FY24) to $237.0M (FY25). Paying ~$258M cash for 24% of an asset now generating $237M of 100%-owned NOI looks cheap in hindsight; even at the time it concentrated capital into the demonstrably best business — textbook “double down on your winner.”

7.3 Acquisition cadence — disciplined, off-market, operator-anchored

FACT. FY25: >$950M of acquisitions (aggregate contract price), taking the portfolio to ~$5.4B. The investment team sourced ~$590M of SHOP across 14 transactions/18 communities with over one-third off-market, formed two new regional operator relationships (~$480M) and supported Trilogy’s $195M senior-living portfolio buy (proxy CD&A). 2026: $650M+ awarded pipeline (mostly SHOP, ~80% with existing operators, targeted to close by Q3), $249M closed YTD, plus $173.9M of Trilogy development (campus expansions / independent-living villas; $52.4M funded) (Q1’26 call/10-Q). Stabilized yields “in the 7s,” below replacement cost. INTERPRETATION: the discipline markers are all favorable — off-market sourcing (avoids auctions), buying through existing operators (lower operational risk), development at higher yields, and a clear cost-of-capital spread (7%+ yields vs a ~5–6% blended cost of the equity+debt funding the deals). Marathon capital-cycle caveat (from Industry): cap rates in senior housing have compressed 25–50bps and “more players are entering” — the 7-handle yields are already tightening, so the spread that makes the model work is narrowing even as it’s being pressed hardest.

7.4 The reflexive accretive-equity engine — the central capital-allocation risk

FACT. Share count has ~tripled: ~66M (FY22–23) → 131M (FY24 avg) → 166M (FY25 avg) → 185.9M (YE25) → 189.9M (Mar 31, 2026), plus ~10.7M unsettled forward shares and OP units. The machinery: a 2025 ATM ($1.0B, terminated Feb 27 2026 with $230M unsold) replaced same-day by a 2026 ATM of up to $1.75B; a November 2025 follow-on of 9.315M shares at $48.00 = $447.1M gross; and forward sale agreements with 10.69M shares unsettled at an avg $50.28 = $537.6M of locked-in future proceeds (settled post-Q1: another 2.76M @ $48.60 = $134.0M). INTERPRETATION — name the risk directly: AHR is running the classic reflexive REIT growth flywheel — issue equity at a premium multiple (~24x forward NFFO / above NAV), deploy into ~7% assets, book the spread as per-share accretion, which supports the multiple, which enables the next raise. It is genuinely accretive today (issuing at $48–50 into ~7% yields with a low cost of equity is per-share-positive, and doing so above NAV is unusual and favorable for a REIT — most healthcare REITs trade below NAV and dilute when they issue). But the engine only runs while the multiple holds. If AHR de-rated toward the peer 12–18x P/NFFO range, the cost of equity would spike, the accretion would invert to dilution, external growth would stall, and the stock’s premium — which is partly built on the expectation of continued accretive growth — would compress further. The balance sheet is safe; the growth algorithm is multiple-dependent and self-reinforcing in both directions. This is the key variant-perception input.

7.5 SBC and the operator-incentive equity plan — novel alignment, real dilution

FACT. The non-cash SBC add-back rose to $14.6M in FY25 (from $9.4M) and will climb further. AHR adopted a 2025 Manager Equity Plan (max 1,000,000 shares) — separate from the 4.0M-share 2015 employee plan and the ESPP — expressly to pay AHR stock to its RIDEA operators/managers. First use: on Nov 10, 2025 it granted a RIDEA Manager 73,734 time-based RSUs + 73,734 performance-based RSUs (up to 115,099 shares at max, cliff-vesting 12/31/2027) (10-Q, Note 12). INTERPRETATION: this is a thoughtful, unusual alignment tool — tying third-party operators’ payoff to AHR’s share price should sharpen their incentive to grow NOI and occupancy (the operator, not AHR, controls day-to-day performance). It validates the “reward operators with equity” strategy management flagged. The cost is real dilution and it deepens AHR’s dependence on a high share price to make the incentive potent — another strand of the reflexivity. Worth tracking as the plan scales toward its 1.0M-share cap.

7.6 Dividend policy — conservative to a fault

FACT. Quarterly distribution $0.25/share, $1.00 annualized, unchanged since Q1 2023 (10-K Item 5). On 2025 NFFO of $1.72, that is a ~58% payout; on Q1’26 NFFO of $0.50, 50%. Yield at ~$53.57 is ~1.9% — low for a healthcare REIT (peers 3–5%). A portion has been characterized as return of capital. INTERPRETATION: the payout is genuinely conservative and leaves ample room to grow the dividend — but management has chosen not to raise it for 3+ years even as NFFO/sh compounds >20%. Holding the dividend flat while NFFO/sh rockets means the yield has been crushed by the re-rating; income buyers have been effectively priced out, and the equity has become a pure total-return/growth vehicle. Retaining ~$0.72/sh of NFFO to help self-fund development is defensible capital allocation, but the stinginess is notable and slightly at odds with the “IG-quality, best-multiple” positioning.

7.7 Dispositions — pruning at (recognized) losses

FACT. FY25 dispositions: one SHOP, two ISHC, ten OM buildings, one triple-net property, ~$44M gross proceeds, at a net loss on disposition of $2.965M and preceded by ~$49.9M of OM impairments. Over the cycle AHR has sold >1/3 of the OM book and continues to shed triple-net. INTERPRETATION: strategically right (concentrate into operating senior housing where the demographic tailwind and moat live), but executed at losses to book — the OM/NNN legacy assets were worth less than carried, and shareholders are absorbing that as the portfolio is high-graded. Direction good; the round-trip economics on the legacy book are poor.

7.8 Compensation & incentive alignment

FACT (DEF 14A, 2026-04-09). 2025 base salaries: CEO Prosky $800k, CFO Peay $525k, Willhite $475k, Oh $440k, Foster $395k. Short-term (cash) incentive: 70% corporate / 30% individual; corporate metrics = Normalized FFO per share (60% weight) + Same-Store NOI Growth (40% weight); payout scale 50%/100%/150% (threshold/target/max). Net Debt-to-Adjusted EBITDA was removed as a 2025 metric (“already successfully reduced leverage”). Long-term equity: performance RSUs cliff-vest on relative TSR vs a 9-company healthcare-REIT peer set (CareTrust, Healthcare Realty, LTC, National Health Investors, Healthpeak, Sabra, Omega, Ventas, Welltower); 50% payout at 25th percentile, 100% at 50th, 200% at 75th, zero below all peers. CEO target pay is 84.9% at-risk; other NEOs 75.5%. Cumulative TSR since the Feb-2024 listing: $100 → $385.26 vs peer-group $181.49. INTERPRETATION: metric selection is sound and REIT-appropriate (NFFO/sh + SS-NOI + relative TSR are exactly what shareholders should want, and relative-TSR guards against a rising-tide payout). Two soft spots: (i) the Compensation Committee scored the individual component at maximum for every NEO — a discretionary generosity that dilutes the objectivity; (ii) dropping the leverage metric removes a balance-sheet guardrail just as the equity engine incentivizes asset-base growth. Alignment is above-average but not airtight.

7.9 Insider behavior — uniformly selling into the run, zero conviction buys

FACT (Form 4 / Form 144 corpus, EDGAR, sampled Jun 2026 cluster + trailing 12 months; 173 Form 4s / 9 Form 144s over the 5-yr set):

• June 2026 cluster is all sales + routine grants — no purchases. CFO Brian Peay sold 25,000 shares @ $50.696 on 6/26/26 ($1.267M; 144 confirms), holding 152,700 after (code S, discretionary). GC/EVP Mark Foster sold 2,500 @ $48.58 (6/24), 2,000 @ $48.32 (6/1), and 2,000 @ $48.83 (3/25 per 144). The eight-director filings dated 6/24 are the annual board equity grant (code A, 2,594 shares each at $0) — grants, not open-market buys.
• The founder/Chairman & current Interim CEO, Jeffrey T. Hanson, is himself a seller: code-S sales on 11/10/2025 (@ $49.68) and 12/22–23/2025 (@ ~$48.38–48.40).
• Zero open-market purchases (code P) appear in the sampled corpus — every discretionary transaction by a named officer/director is a sale; the only acquisitions are RSU vesting (M/A/F codes) and the annual director grant.
• Nine Form 144 planned-sale notices over the trailing year corroborate an ongoing, programmatic disposition pattern (largely 10b5-1-style planned sales, but discretionary in the sense that insiders chose to establish selling plans as the stock hit record highs).
• Insider ownership is modest (each NEO/director <1% of shares; the founders retain OP units via AHI Group Holdings, ~1.0% of the OP). BlackRock is the largest holder at ~24.6M shares (~13%), per the 13G/A.

INTERPRETATION. This is the clearest negative signal in the capital-allocation picture. With the stock up ~4x from IPO and pinned near its all-time high, the entire named insider group — including the CFO and the founder now running the company — is selling, and not one is buying in the open market. That is not proof of a top (insiders of a former non-traded REIT with concentrated legacy holdings have legitimate diversification reasons, and the sales are individually small relative to the float), but it is the opposite of the conviction-buy signal that would corroborate the bull case at this valuation. It belongs directly in Claude’s Take and Variant Perception as evidence that those closest to the numbers are taking chips off the table into the re-rating, not adding.

7.10 Verdict — has management allocated capital intelligently?

Mostly yes, with two real caveats. The affirmative case is strong: (i) deleveraged first (net debt/EBITDA 4x+ → 3.0x, all floating swapped to fixed); (ii) concentrated capital into the best asset via the 2024 Trilogy buy-in; (iii) acquired discipline — off-market, operator-anchored, ~7% yields below replacement cost; (iv) issued equity above NAV at a premium multiple — genuinely accretive and unusual for a REIT; (v) pruned the low-moat OM/NNN legacy. The caveats: (a) the growth algorithm is reflexive and multiple-dependent — it is accretive today but would invert violently on a de-rating, and cap-rate compression is already narrowing the spread; and (b) the soft signals — a dividend frozen for 3+ years (yield crushed to ~1.9%), maxed-out discretionary bonus components, a dropped leverage metric, chronic dispositions at losses to book, and uniform insider selling with zero buys into the all-time high. Capital allocation has created value to date; whether it continues to depends less on management’s skill than on the market’s continued willingness to pay ~24x forward NFFO — which is exactly the condition the insiders appear to be monetizing.

8. Changes and Headwinds — Last Two Years

The last twenty-four months reshaped AHR from a sleepy, over-diversified, non-traded retail REIT into a concentrated, institutionally-owned operating-senior-housing/care compounder — and simultaneously repriced it from ~$13 to ~$54. Every major change below pulls in the same direction operationally (a better, cleaner, faster-growing, less-levered business) while raising the valuation and cyclical stakes. The two cannot be separated.

1. The February 2024 IPO / listing (FACT). The defining structural event. AHR was assembled in 2021 from Griffin-American Healthcare REIT III, Griffin-American Healthcare REIT IV, and the internalized external manager (American Healthcare Investors), and traded as a non-traded retail REIT until the NYSE listing at $12. Listing gave it (a) a public currency to issue accretively, (b) analyst coverage, and © liquidity — the three ingredients of the subsequent re-rating. Interpretation: the entire investment case rests on the durability of the premium public currency the listing created.

2. Trilogy consolidation — 100% ownership (FACT, Sept 20, 2024). AHR bought the remaining 24% of Trilogy REIT Holdings for $258M cash ($247M base + $11M true-up), taking full ownership of the Integrated Senior Health Campuses (ISHC) segment — the largest contributor to NOI and, per management, “the most durable competitive moat in our entire portfolio.” Interpretation: this both increased AHR’s economic interest in its best assets and concentrated the portfolio’s risk into a single operator/segment (see Risk Matrix). It is thesis-strengthening on quality and thesis-concentrating on risk.

3. Portfolio simplification — OM and net-lease dispositions (FACT). AHR has sold more than one-third of its outpatient-medical (OM/MOB) book and is shrinking the triple-net-leased segment (now <6% of NOI). Proceeds recycle into SHOP acquisitions (YTD 2026 acquisitions were 100% SHOP, all with existing operators). Interpretation: this deliberately trades lower-volatility, lower-growth net-lease/MOB cash flows for higher-growth, higher-beta RIDEA operating income — raising both the growth rate and the cyclicality of the earnings stream. The book is now overwhelmingly operating-intensive (Trilogy + SHOP).

4. CEO Prosky medical leave; Hanson interim (FACT, Feb 2026 — key-person / governance). CEO Danny Prosky took medical leave in February 2026; Chairman and predecessor-entity founder Jeffrey T. Hanson stepped in as Interim CEO/President. Prosky underwent a successful procedure (~April 2026) and is recovering, with no announced reentry timeline. Interpretation: a genuine key-person overhang partially mitigated by founder continuity in the interim seat. It has not visibly disrupted execution (Q1’26 was a beat-and-raise), but an open-ended leadership gap at a company mid-transformation is a real governance item, not a footnote.

5. Balance-sheet de-levering to 3.0x (FACT). Net debt/EBITDA improved to 3.0x at Q1’26 (from 3.4x at YE2025), funded by ATM forward equity sales (8.1M shares / $412.7M priced; $527.4M unsettled forwards; >$1B available) and an upsized $600M→$800M revolver extended to 2030 with $0 drawn. Management is explicit that low leverage “helps equity trade at best multiple.” Interpretation: this is genuinely prudent and lowers financial risk — but it is also self-referential: the de-levering is financed by issuing premium-multiple equity, so the balance-sheet strength and the rich multiple are two ends of the same reflexive loop.

6. Reimbursement backdrop — CMS SNF rate + MA deceleration (FACT/headwind). The CMS FY-preliminary SNF market-basket update was ~2.4%, and Medicare Advantage rate growth is decelerating from its recent peak. Trilogy’s model leans on a rising quality mix (75.5%, +60bps) and ~+5%/yr SNF rate gains (private-pay + MA selectivity; MA rate +6.6% last quarter). Interpretation: the reimbursement tailwind that has helped drive >20% NOI margins is moderating. A flatter Medicare/MA rate environment, or a Medicaid squeeze at the state level, would pressure the SNF-heavy Trilogy engine directly.

7. Labor (FACT/ongoing headwind). Senior housing and skilled nursing are labor-heavy (labor is the dominant SHOP/SNF operating-expense line). The current margin expansion (SHOP NOI margin 20.6%, +215bps; Trilogy >20%) depends on wage growth staying moderate against occupancy-driven operating leverage. Interpretation: a wage re-acceleration would compress margins quickly in an operating-intensive book — this is the same cyclical knife that cut senior-housing REITs in 2020–2022, now pointing the other way.

Verdict — do these changes strengthen or weaken the thesis? On the business, they strengthen it decisively: a cleaner, more concentrated, faster-growing, less-levered franchise centered on the best-positioned niche in real estate, with 100% ownership of its crown-jewel operator. On the stock, they raise the stakes: the same moves that improved the business also (a) increased operating/labor/reimbursement cyclicality, (b) concentrated risk into Trilogy and into a reflexive equity-issuance model, and © left a key-person overhang — all while the multiple re-rated to the top of the sector. Net: a materially better business at a materially more demanding price. The changes are thesis-positive on quality and thesis-tightening on valuation and cyclicality.

9. Risk Analysis (Risk Matrix)

Top risks in prose.

1. Multiple compression is the central risk (Med-High likelihood, High impact). AHR trades at ~24.5x forward and ~31x trailing NFFO, a ~1.9% dividend yield, and the 98.9th percentile of its own (admittedly short) price-to-sales history — the richest-ever tell on the one valuation metric not distorted by REIT accounting. It is priced alongside Welltower, the highest-quality, A-rated, best-run name in the group, despite a shorter public track record, a majority-SNF operating book, and a key-person overhang. Most healthcare REITs trade 12–18x. Interpretation: the dominant realistic downside is not insolvency (leverage is low, assets are hard) but a de-rating — a good business repriced from ~24x toward a still-premium-but-saner high-teens as growth normalizes or rates rise. With only a 1.9% yield, there is no income cushion to catch that move; a 25% multiple compression on flat NFFO is a ~25% price decline. This is the shape of the risk.

2. Reflexive dependence on premium equity (Med likelihood, High impact). AHR’s growth model is the same flywheel as WELL/VTR: a premium multiple → cheap equity via the ATM/forwards → accretive acquisitions at ~7% stabilized yields → higher per-share NFFO → premium multiple. It works spectacularly while the multiple holds and reverses fast when it doesn’t. The de-levering to 3.0x, the >$1B of available equity capacity, and the $650M+ pipeline all assume continuous access to premium-priced equity. Interpretation: the balance-sheet strength and the growth rate are both endogenous to the high multiple — a de-rate would simultaneously raise AHR’s cost of equity, slow accretive deployment, and remove the very support the low leverage was meant to provide. The risk is self-reinforcing on the way down.

3. SHOP/SNF operating and reimbursement cyclicality (Med likelihood, High impact). The portfolio is now overwhelmingly RIDEA operating income (Trilogy + SHOP), where labor is ~60% of operating cost and revenue is repriced frequently. The current margin expansion — Trilogy NOI >20%, SHOP 20.6% (+215bps) — is the joint product of occupancy recovery and moderate wage growth. Both are cyclical. Layer on a decelerating reimbursement backdrop (~2.4% CMS SNF update, slowing MA rates) and the Trilogy engine’s reliance on rising quality mix and ~+5%/yr SNF rate, and the same operating leverage that is inflating NFFO today would deflate it in a wage-reacceleration or reimbursement-squeeze scenario. Interpretation: the 20%+ NFFO growth is a recovery-plus-leverage rate, not a structural constant; its durability is the master variable.

4. Operator/segment concentration in Trilogy (Med likelihood, High impact). With Trilogy/ISHC the majority of NOI and now 100%-owned, AHR’s fortunes are heavily tied to a single operator (Trilogy Management Services) and a single sub-model (integrated campuses in largely Certificate-of-Need states). This is the moat and the concentration risk in one asset. Interpretation: the CON-driven supply constraint is a genuine advantage, but a single-operator operational stumble, a state-level Medicaid action, or a CON regime change would hit a disproportionate share of NOI.

10. Valuation Discussion (embedded expectations)

Sector-appropriate metrics only. REIT GAAP EPS and P/E are meaningless here (depreciation distortion); the relevant frame is P/NFFO, implied cap rate, EV/EBITDA, NAV, and dividend yield. No price target, no recommendation.

Where it trades (FACT). At $53.57, AHR is:

• ~24.5x forward NFFO on the 2026 guide midpoint of ~$2.19 ($2.09–$2.30 range), and ~31x trailing NFFO on ~$1.73 2025 NFFO/share.
• EV/TTM EBITDA ~24.9x; EV/TTM sales ~4.4x (ROIC EV ~$10.43B; net debt ~$1.56B).
• ~1.9% dividend yield (~$0.98/share, ~57% NFFO payout — conservative, with room to grow).
• 98.9th-percentile own-history price-to-sales (AZI valuation_index) — the richest the stock has ever been on the one clean metric. (P/E percentile ignored — GAAP-distorted; P/B ignored — garbled data field, cf. NEM gotcha.)
• Net debt/EBITDA 3.0x — the lowest leverage in the peer set, a deliberate choice to support the multiple.

Implied cap rate (Interpretation). AHR is deploying fresh capital into SHOP at stabilized yields “in the 7s,” below replacement cost. The public equity, at ~24.5x forward NFFO and a mid-20s EV/EBITDA, is valuing the in-place operating book at a materially tighter implied cap rate than the ~7% at which AHR itself buys comparable assets privately — the same “the market pays more for the buildings than the company can buy them for” tell that defines WELL. That gap is the embedded-expectations signature of a premium-multiple operating REIT.

Comp table (2026E; peer figures from prior internal notes — WELL 2026-06-12, VTR 2026-06-26, DOC 2026-07-11 — as prior analysis).

Interpretation: AHR now sits at the top of the healthcare-REIT multiple range, next to Welltower — not in the 12–18x cohort where most healthcare REITs (and essentially all SNF-heavy names) trade. It slots above Ventas despite Ventas’s larger scale and longer public record, and it commands roughly double the DOC / net-lease multiple. The bull justification is that AHR’s blended operating same-store NOI (Trilogy +14.5%, SHOP +19.7%) and its 3.0x leverage rival or exceed the group. The bear observation is that AHR is being paid a WELL-like multiple with a majority-SNF book (structurally lower-margin, more reimbursement-exposed, and historically lower-multiple than pure senior housing), a ~2.5-year public track record, and a key-person overhang.

Embedded expectations — what does $53.57 require? (Interpretation/Assumption). A REIT’s total return ≈ NFFO growth + NFFO yield ± multiple change. At $53.57, the forward NFFO yield is ~4.1% and the cash (dividend) yield only ~1.9%. Reverse-engineering the price on a five-year hold from the 2026 base NFFO of ~$2.19:

• To earn a ~10% five-year IRR with the multiple holding at ~24.5x, NFFO/share must compound at roughly ~8%/yr (≈$3.22 by 2031), with the ~1.9–2% yield making up the balance. That is well below AHR’s current ~20% pace but assumes no multiple mean-reversion at all — a heroic assumption for a stock at its richest-ever P/S.
• To earn a ~10% IRR while the multiple compresses to ~18x (still a premium to the sector, below WELL), the de-rate costs ~6%/yr, so NFFO must compound at roughly ~14%/yr for five years (≈$4.2 by 2031) just to stand still on return — i.e., the current 20% growth must barely decelerate for half a decade. That is a demanding, momentum-dependent bar.
• Put differently, at ~24.5x the market is underwriting years of mid-teens-to-20% NFFO growth and durable retention of a top-of-sector multiple and uninterrupted accretive equity issuance — three assumptions that must all hold.

Scenario framing (explicit assumptions; no price target).

• Bear: SHOP/Trilogy same-store NOI decelerates below ~8–10% as occupancy fills and wage/reimbursement pressure returns; NFFO growth fades to mid-single digits; the multiple de-rates from ~24.5x toward the ~16–18x historically carried by SNF-heavy operating REITs. Flat-to-modest NFFO against a ~30% multiple compression is a materially lower equity value, with only a 1.9% yield to cushion it.
• Base: Same-store NOI decelerates gradually toward low-teens; NFFO compounds ~8–12% on organic operating leverage plus accretive SHOP deployment; the multiple holds ~20–24x as growth stays visibly above peers. Total return tracks NFFO growth plus the ~1.9% yield — high-single-to-low-double digits, most of it earnings-driven, little from further re-rating.
• Bull: The demographic supercycle plus record-low supply sustains 15–20% NFFO growth for several years; the accretive-issuance flywheel keeps compounding at 3.0x leverage; AHR fully earns a durable WELL-like multiple (~28–33x). Total return is compounding-plus-re-rate — the momentum case extended.

What the market is underwriting correctly vs. incorrectly (Interpretation). Correctly: the demographic tailwind (80+ population inflection accelerating), the record-low new-supply backdrop, the genuine occupancy runway (Trilogy 91.2%, SHOP 88.6% — both with room), and the unusually low 3.0x leverage that gives AHR real capacity to fund growth. Potentially incorrectly: that ~20% NFFO growth annualizes indefinitely (it is a recovery-plus-leverage rate, not a constant); that a richest-ever multiple mean-reverts not at all; that capital does not return to compress the ~7% acquisition yields the flywheel depends on (cap rates are already compressing 25–50bps); and that the reflexive equity-issuance engine keeps working even if sentiment shifts. Verdict — Valuation: AHR is priced for continued high-teens/20% NFFO compounding and retention of a top-of-sector multiple and an uninterrupted accretive-issuance flywheel. The business may deliver the first; the cushion for a disappointment in any of the three is thin (1.9% yield, richest-ever P/S), and most of the easy re-rating — ~4x off the IPO — is behind the stock, not ahead of it.

11. Variant Perception

Consensus belief. The sell-side is uniformly, and recently, bullish — a crowded long. In the weeks before this report: Citi upgraded to Buy (Jun 23), Barclays initiated Overweight (Jul 7), UBS reiterated Buy and raised its target to $63 (Jul 8), and Scotiabank held Sector Outperform (Jun 18). The crystallized consensus narrative: AHR is the fastest-growing way to play the senior-housing/care supercycle — nine straight quarters of double-digit same-store NOI, 20%+ NFFO growth, 3.0x leverage, and a self-funding accretive-issuance flywheel that deserves a Welltower-like multiple. The tape corroborates the crowding: y1 return +51%, Sharpe 2.02, max drawdown only −13.6%, beta 0.46, alpha +0.77 — a textbook low-volatility one-way-street-up, sitting ~2.7% below its all-time high.

Strongest bull case. The demographic supercycle is the most visible tailwind in real estate (80+ population inflecting up on a fixed biological clock through the 2030s) while new senior-housing supply sits near historic lows because construction does not pencil below replacement cost. AHR captures it with operating leverage (occupancy still has runway: Trilogy 91.2%, SHOP 88.6%), a genuine Trilogy moat (CON-driven SNF supply constraint that is net-negative on beds, integrated campuses, operator relationships, dynamic-pricing software), and a reflexive flywheel funded at just 3.0x leverage with >$1B of equity capacity. That combination can plausibly sustain 15–20% NFFO growth for years — and if it does, a WELL-like multiple is earned, not stretched.

Strongest bear case. Strip the narrative and AHR is a leveraged bet on the senior-housing occupancy cycle wrapped around a reflexive equity-issuance machine, trading at its richest-ever multiple. The growth is a recovery-plus-operating-leverage rate (labor ~60% of opex; reimbursement decelerating), not a structural constant; when same-store NOI normalizes toward single digits, a ~24.5x multiple on a majority-SNF operating book looks like WELL’s price for a lower-quality, shorter-track-record, key-person-impaired franchise. Multiple compression + growth deceleration + a SHOP labor or SNF-reimbursement air-pocket would de-rate the stock toward the high-teens with no yield cushion (1.9%) to catch the fall — and the same de-rate would break the accretive-issuance flywheel that the whole model depends on. The negative Quality factor loading (−0.21) is the tape’s quiet admission that this is a low-margin operating business, not a fortress annuity.

The 3–5 assumptions that matter most, and what falsifies each side.

1. Durable same-store NOI / NFFO growth rate post-occupancy-normalization. Bull needs: mid-teens-plus sustained. Bear needs: deceleration below ~8–10%. Falsifier: two or more consecutive quarters of SHOP/Trilogy same-store NOI below ~10% (bull broken); or continued double-digit prints as occupancy crosses the low-90s (bear broken).
2. Multiple durability. Bull: a top-of-sector ~24–33x holds. Bear: mean-reversion toward the 16–18x SNF-heavy operating REITs historically carry. Falsifier: a rate shock or growth wobble that compresses the multiple with no yield support confirms the bear; multiple holding through a growth pause confirms the bull.
3. The accretive-issuance flywheel. Bull: premium equity keeps funding ~7%-yield deals. Bear: cap-rate compression (already 25–50bps) plus a lower multiple stalls the treadmill. Falsifier: acquisition yields drifting below the cost of capital, or an inability to issue equity accretively, breaks the bull.
4. Reimbursement and labor. Bull: rising quality mix + moderate wages sustain 20%+ margins. Bear: MA deceleration / Medicaid squeeze / wage re-acceleration compresses the SNF-heavy book. Falsifier: a Medicare/Medicaid rate action or wage reacceleration that visibly compresses Trilogy NOI margin.
5. Key-person / concentration. Bull: founder continuity bridges Prosky’s leave with no execution loss. Bear: an open-ended leadership gap plus Trilogy single-operator concentration is a latent governance/operational risk. Falsifier: any Trilogy operational stumble, or a disorderly CEO transition.

Factor-positioning read (FactorsToday; third-party statistical estimates, not primary). The empirical positioning corroborates the bear’s risk framing without settling the fundamental debate. AHR loads positively on Real Estate sector (+0.75), Market (+0.68), REITs industry (+0.40), LowVolatility (+0.21) and Momentum (+0.12) — i.e., a crowded, low-vol, momentum-favored long riding a favorable regime. It loads negatively on Quality (−0.21) — the model reads it as a low-margin operating REIT, not a high-quality annuity — and on InterestRate (−0.25), flagging genuine rate/duration sensitivity that the 1.9% yield does nothing to cushion. Interpretation (regime-caveated): the same low-volatility momentum that has driven the +51% year is exactly what unwinds fastest if the favorable factor regime (falling-rate expectations, momentum-in-favor) reverses. The tape says “one-way street up”; the factor loadings say the street is crowded, low-quality, and rate-sensitive — consensus is positioned for continuation, which is precisely where a variant perception has its edge. Treat as positioning input, not a price call.

Verdict — Variant perception. Consensus (uniformly bullish, crowded long) and the bull case are largely correct on the business — this is a genuinely good franchise in a genuinely good industry. The variant edge is on the price and the positioning: a richest-ever multiple, a 1.9% yield with no cushion, a recovery-rate growth number the market is extrapolating as structural, a reflexive flywheel that reverses if the multiple breaks, and a crowded low-vol/momentum factor stance — all of which sit uneasily beneath a WELL-like valuation on a lower-quality, majority-SNF, key-person-impaired book. The debate resolves on the durable same-store NOI growth rate once occupancy normalizes; everything else is a derivative of that one variable.

12. Fact vs. Interpretation Table

13. Open Questions

1. What is the durable same-store NOI growth rate once occupancy normalizes into the mid-90s? This is the master variable; the current +12–20% is a recovery-plus-operating-leverage rate that must decelerate. (Open — the entire valuation debate resolves here.)
2. Why does AHR not disclose AFFO / a maintenance-capex reconciliation? For an operating-intensive senior-care REIT, recurring capex is material; its absence makes the ~24x forward NFFO look optically cheaper than a like-for-like AFFO multiple. (Diligence item.)
3. What is CEO Danny Prosky’s return timeline, and what is the succession plan if the leave becomes permanent? Open-ended since February 2026; founder Hanson is bridging, but this is a genuine governance overhang. (Open.)
4. How much further can the accretive-issuance flywheel run as cap rates compress? Acquisition yields “in the 7s” are already tightening 25–50bps; at what spread does external growth stop being accretive? (Open — capital-cycle dependent.)
5. How exposed is Trilogy to a state-level Medicaid action or a Medicare Advantage rate reset? The SNF-heavy core leans on a rising quality mix and above-inflation rate gains that a policy shift could reverse. (Open — policy-dependent.)
6. What is the exact UK / Isle of Man exposure and its FX/reimbursement profile? Disclosed as part of the footprint but not sized in this pass. (Open — data gap.)
7. Is the reported same-store universe being reconstituted in a way that flatters growth? Management acknowledged shifting non-stabilized assets into the SHOP same-store pool (which lowers RevPOR but boosts NOI growth). (Open — quality-of-disclosure item.)

14. What Must Be True

For the BULL case to be right (a durable compounder that earns its WELL-like multiple):

1. Same-store NOI growth must stay durably in the low-teens-plus even as occupancy crosses into the low-90s — i.e., rate/quality-mix and margin expansion must offset the mathematical fade of the lease-up recovery.
2. The premium multiple (~24x+ forward NFFO) must hold, keeping the accretive-issuance flywheel spinning at positive spreads despite compressing cap rates.
3. The reimbursement and labor backdrop must remain benign — quality mix keeps rising, wages stay moderate, no Medicaid/MA shock to the SNF-heavy Trilogy engine.

Bull falsification test: two or more consecutive quarters of SHOP/Trilogy same-store NOI below ~10%, or acquisition yields drifting to/below the cost of capital (flywheel stalls), or a visible NOI-margin compression from wages/reimbursement. Any one materially damages the bull.

For the BEAR case to be right (a de-rating of a cyclical, reflexively-financed operating REIT at its richest-ever multiple):

1. The ~20% NFFO growth must prove to be a recovery-plus-leverage rate that decelerates toward mid-single digits as occupancy fills and reimbursement moderates.
2. The multiple must mean-revert from ~24x toward the 16–18x that SNF-heavy operating REITs historically carry — with only a 1.9% yield to cushion the move.
3. Some combination of a rate shock, a cap-rate/capital-cycle turn that breaks the accretive-issuance spread, or a labor/reimbursement air-pocket must materialize to trigger the re-rating.

Bear falsification test: continued double-digit same-store NOI prints as occupancy crosses the low-90s (proving the growth is structural, not just lease-up), or the multiple holding through a growth pause / rate move (proving the premium is durable), or an insider open-market purchase signaling conviction at these levels. Any one materially damages the bear.

The two cases share one hinge: the durable organic growth rate once occupancy normalizes. A believer in mid-teens-forever should own it through the premium; a believer in single-digits-eventually should wait for the de-rate the bear requires. This article takes no side beyond the labeled Claude's Take.

APPENDIX A — Standard Diligence Questionnaire

American Healthcare REIT, Inc. (NYSE: AHR) · Report date 2026-07-11 · Price $53.57

Supplemental to the research memo (not counted toward memo length). No price target, no BUY/SELL. Labels: Fact (traceable to a filing, transcript, or data feed), Interpretation (our read of the facts), Assumption (unverified inference). All figures from the research log unless a new source is named.

General

What thoughtful questions have other investors asked about this company?

The sell-side is uniformly bullish and crowded-long (Citi Buy Jun 23; Barclays Overweight Jul 7; UBS Buy, PT $63 Jul 8; Scotiabank Sector Outperform Jun 18) — Fact. When the analyst community is this one-sided, the sharpest questions are the ones being under-asked, not the ones getting airtime. Drawing on the Q1’26 call Q&A, sell-side notes, and the structural setup, the questions that actually move the thesis are:

• SHOP cap-rate compression / sources-and-uses: AHR is buying only SHOP, all with existing operators, at “stabilized yields in the 7s” below replacement cost — but management itself flagged cap rates compressing 25–50 bps and “more players entering” (Fact). The real question: how long does the accretion spread survive as capital returns to senior housing? The entire external-growth engine is reflexive — cheap equity (richest-ever P/S, ~24.5x forward P/NFFO) funds accretive deals only while the multiple holds (Interpretation). Investors should press on what the pipeline yield looks like if the equity de-rates to peer multiples.
• RevPOR / rate deceleration: SHOP and Trilogy have posted nine consecutive quarters of double-digit same-store NOI growth (Q1’26: total SS NOI +12.1%; Trilogy +14.5%; SHOP +19.7%) — Fact. This is a post-COVID occupancy-recovery level-shift, not a permanent run-rate. The thoughtful question is when does SS NOI growth normalize toward mid-single-digits, and what does the multiple do when it does (2026 guide already steps down the SS NOI range to 9–12%) — Fact/Interpretation.
• CMS / Medicare Advantage reimbursement: Trilogy’s margin story leans on quality mix (75.5%), SNF rate +5%/yr, and MA rate +6.6% last quarter (Fact). Investors ask: how exposed is the SNF book to CMS rate actions, MA plan rate pressure, and state Medicaid? A single adverse MA/Medicaid cycle compresses the highest-margin piece.
• Trilogy margin runway: NOI margin crossed 20% for the first time since COVID (+134 bps in 2025). How much recovery is left vs. how much is already priced? (Interpretation — the market appears to extrapolate continued margin expansion.)
• Development pacing & funding: $650M+ awarded pipeline plus $173.9M development (only $52.4M funded). Can AHR fund the pipeline without dilutive equity if the stock stops cooperating? (Open question.)
• Governance / key-person: CEO Danny Prosky on medical leave since Feb 2026; founder/Chairman Jeffrey Hanson interim, no reentry timeline (Fact). Investors ask about succession clarity.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? Senior-housing fundamentals are still climbing out of a COVID trough, so operating earnings are early-to-mid cycle, not peak — occupancy is recovering (Trilogy SS occ 91.2%, +~220 bps YoY; SHOP SS occ 88.6%, +~255 bps YoY) and NOI margins only just crossed 20% “for the first time since COVID” (Fact). But the valuation is at a cyclical high: P/S is at its 98.9th percentile (richest-ever on sales), forward P/NFFO ~24.5x, dividend yield down to ~1.87% (Fact). So the honest read is: fundamentals mid-recovery, price fully-to-over-extrapolating that recovery (Interpretation).

Driven by external environment or internal actions? Both, and it matters which. The external driver is the post-COVID occupancy/rate recovery plus the 80+ demographic inflection against historically low new supply — the same tailwind lifting WELL and VTR (Fact). The internal actions are real but reflexivity-dependent: the 100% Trilogy buyout ($258M for the last 24%), the SHOP acquisition spree with existing operators, the OM/triple-net disposals concentrating the book into operating senior housing, and the deleveraging to 3.0x (Fact). Interpretation: the double-digit SS NOI growth is mostly external cyclical recovery; management’s internal execution amplifies it but did not create it. Cyclical-recovery earnings should not be capitalized at a secular-growth multiple.

How stable are revenues? Less stable than a net-lease REIT. AHR is now a RIDEA/operating REIT (SHOP + Trilogy consolidate operator-level revenue), so it takes direct occupancy, labor-cost, and reimbursement risk rather than collecting contractual rent (Fact). EBITDA margin sits at ~17–18% and has been flat because consolidated operator revenue dilutes the margin optics (Fact). Revenue has compounded steadily (FY22 $1.62B → FY25 $2.26B → TTM $2.37B, ~+10–14%/yr — Fact), but the quality of that revenue is operating, not contractual. Triple-net (contractual, stable) is now <6% of NOI and shrinking (Fact).

Outlook for products/services: 2026 NFFO/sh guide raised to $2.09–$2.30 (mid ~$2.19, +20% over 2025); SS NOI guide 9–12% (Trilogy 11–15%, SHOP 15–19%, OM 0–2%, triple-net 2–3%) — Fact. Positive but decelerating off the recovery peak (Interpretation).

Market size — growing/shrinking, domestic/international? Growing: the 80+ population inflection is accelerating and new senior-housing starts are near historic lows because construction doesn’t pencil below replacement cost — a demand->>-supply setup through the ~2030s (Fact/Interpretation, same structural thesis as WELL/VTR). Footprint is 36 US states + United Kingdom + Isle of Man (Fact); the UK/Isle of Man exposure is small but real and adds FX and foreign-reimbursement wrinkles (size not precisely quantified in filings reviewed — Open question).

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More competitive at the margin. Management itself said cap rates have compressed 25–50 bps and “more players entering” senior housing (Fact). In Marathon/Capital Returns terms, senior housing is a supply-constrained inflection that has begun attracting capital — high returns are pulling money in, which is precisely the condition that eventually mean-reverts the excess return (Interpretation). The supply of new construction is still low (doesn’t pencil), but the supply of acquisition capital is rising — those are different cycles, and the second one erodes AHR’s buy-side accretion first.

How profitable is the business — and why book-ROIC is the wrong metric? GAAP/book ROIC and ROE are not meaningful for a REIT and should be ignored here (Fact/Interpretation). Reasons: (1) real estate is carried at depreciated historical cost, so the denominator (book capital) is understated and the numerator (GAAP net income) is suppressed by large non-cash depreciation and chronic impairments; (2) AHR only turned GAAP-positive in FY25 (+$70M, EPS +$0.42) and largely because the share count ballooned and interest fell — not because operations inflected (Fact). The AZI P/B reading is a data error (book_value_per_share = 18,522) and must be discarded (Fact, cf. the NEM garbled-line gotcha).

The correct profitability lenses for a healthcare REIT:

• NOI yield / cash-on-cost: acquisitions at “stabilized yields in the 7s,” developments below replacement cost (Fact) — a healthy going-in spread over a ~3.0x-levered, sub-IG-to-IG cost of capital, for now.
• Same-store NOI growth: +12.1% total, nine straight double-digit quarters (Fact) — strong but cyclical.
• NOI margin: Trilogy >20% (first time since COVID); SHOP 20.6% (+215 bps) — Fact. Thin absolute margins typical of operating senior housing; the value is in the direction, not the level.
• FFO/AFFO and NFFO payout (see Valuation) are the earnings analog, not EPS.

How profitable is the industry; competitors; barriers to entry? The industry earns acceptable but not spectacular returns; the operating piece (SHOP) is low-margin and labor-exposed. Competitors: WELL (the premium-multiple SHOP darling), VTR, and Healthpeak/DOC on the medical-office side, plus private operators and PE capital now re-entering (Fact). Barriers to entry differ sharply by segment (Greenwald lens):

• SNF (inside Trilogy): genuine barrier via Certificate-of-Need (CON) in many states restricting bed supply, plus a “bed-license bank” from scale; SNF beds are running net-negative supply (more offline than online) — a real regulatory-captivity + local-scale moat (Fact/Interpretation). Management calls Trilogy “the most durable competitive moat in our entire portfolio” (management claim — hypothesis, validate against the supply data, which broadly supports it).
• SHOP (standalone): thin-to-no durable moat — it is a replicable operating business exposed to local labor markets and new supply where construction pencils (Interpretation, Greenwald).

Can it be easily understood? Moderately. The four-segment structure, RIDEA consolidation, NFFO add-backs, and reflexive equity-funded growth are more complex than a triple-net REIT and require unpacking the operating economics — but it is not opaque (Interpretation).

Can it be undermined by foreign low-cost labor? No. Senior care is inherently local, in-person, and licensed — it cannot be offshored (Fact/Interpretation). If anything the labor risk runs the other way: domestic wage inflation and staffing shortages are the operating cost pressure on SHOP/Trilogy margins.

Do brands matter? Yes, modestly, and mostly at the Trilogy level. Trilogy’s integrated-campus clinical reputation and local density drive referral flow, quality mix (75.5%), and MA-plan selectivity — a form of local intangible/reputation advantage (Interpretation). At the landlord level AHR’s own “brand” is largely irrelevant to residents; the operator brand is what a family chooses (Interpretation).

Nature of competition: competition is for (a) residents/census at the operating level (local, brand/quality/price) and (b) acquisitions at the capital level (cap rates, cost of capital) — AHR is currently winning the second because its multiple lets it pay up accretively, which is exactly the advantage that erodes if the multiple compresses (Interpretation).

Customer switching costs: at the resident level, switching costs are high and organic — moving an elderly resident is disruptive, so census is sticky once placed (real demand-side captivity, Greenwald) (Interpretation). At the operator level, AHR’s deep existing-operator relationships (it buys “with existing operators”) create relationship/switching stickiness on the RIDEA structures (Fact/Interpretation). Neither is contractual the way a 15-year net lease is.

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Yes — this is a REIT, so the real estate sits at depreciated historical cost, materially below current replacement/market value; management explicitly buys and develops “below replacement cost” (Fact). There is embedded, unrecognized value in (a) below-replacement-cost real estate, (b) the CON bed-license bank at Trilogy (a regulatory intangible carried at little/no book value), and © the internalized-management platform. The offset: chronic impairments show that some assets are carried above recoverable value and get written down annually (Fact). Net-net the hidden value is real but the impairments warn it is not uniform (Interpretation).

Off-balance-sheet liabilities? The largest historical one — the Trilogy REIT Holdings JV (AHR owned 76%, then bought the last 24% for $258M in Q3’25) — is now consolidated (100% owned), so that off-balance-sheet exposure has been pulled on-balance-sheet (Fact). Remaining items to watch: operating/ground leases, development commitments ($650M+ awarded pipeline, $173.9M development with only $52.4M funded), and any remaining minority/JV interests (Fact). Nothing in the reviewed filings flags an alarming hidden liability, but the pipeline is a real forward funding obligation (Interpretation).

How conservative is the accounting? Mixed, lean toward aggressive-optics on the non-GAAP line. Points in favor of caution: (1) chronic real-estate impairments every year (FY22 $78M, FY23 $24M, FY24 $46M, FY25 $50M) — the company does write assets down rather than hide them, which is a conservative signal, but the recurrence also says original underwriting was optimistic (Fact). Points that warrant scrutiny: (2) NFFO add-backs are broad — transaction/restructuring costs, $14.6M non-cash SBC, a $23.7M non-cash tax benefit, FX, and derivative marks all get added back, and normalized FFO ($286.5M) is being grown +55% YoY partly through the add-back mix (Fact/Interpretation); (3) the reconciliation from GAAP net income (+$70M) to NAREIT FFO ($293.3M) to NFFO ($286.5M) is a large gap that the reader must inspect, not take on faith. Interpretation: headline NFFO is a legitimate REIT metric but should be stress-tested by stripping the non-cash tax benefit and one-time items before capitalizing it — the run-rate is lower than the reported +55% growth implies.

How CapEx-hungry is the business? More than a net-lease REIT, less than a pure operator. “Free cash flow” and “CapEx-hungry” don’t map cleanly to a REIT — the analog is AFFO after a maintenance-capex reserve plus development/redevelopment capex as the growth spend. AHR carries (a) ongoing SHOP/Trilogy maintenance capex (operating real estate needs recurring reinvestment — higher than an MOB or net-lease asset) and (b) an active development pipeline (Trilogy campus expansions, IL villas; $173.9M, $52.4M funded) (Fact). Growth is funded by equity, not internal cash — CFO ($294M FY25) covers the dividend and maintenance but not the acquisition/development program, which is why AHR is a serial equity issuer (Fact/Interpretation).

Capital Allocation & Management

How much FCF/AFFO, how is it used, what is the philosophy? CFO rose FY24 $176M → FY25 $294M (Fact). NFFO ~$286.5M FY25 (~$1.73/sh). AFFO-equivalent free cash after maintenance capex is thin relative to the growth ambition, so the philosophy is explicitly external-growth via accretive equity: issue shares at a premium multiple (richest-ever P/S), buy SHOP at high-7s yields with existing operators, deleverage to ~IG (3.0x) so the equity “trades at the best multiple,” and let the reflexive loop compound (Fact for the actions; Interpretation for the loop). Dividend takes ~57% of NFFO, leaving retained cash — but not nearly enough to self-fund the pipeline (Fact).

Significant acquisitions? Yes, and central to the thesis: (1) Trilogy 24% buyout — $258M cash, Q3’25, taking AHR to 100% of its crown-jewel platform (Fact); (2) ~$950M of 2025 investment activity (Fact); (3) $650M+ awarded pipeline (mostly SHOP, ~80% existing operators, targeted to close by Q3’26) plus $249.2M YTD acquisitions (100% SHOP) (Fact). Direction: concentrating hard into operating senior housing/care while selling OM (>1/3 sold) and triple-net (Fact).

Buying back shares? No. AHR is a net equity issuer — the opposite of buybacks (Fact). Notable nuance: it issues into a rising, above-NAV price (ATM forward sales 8.1M sh / $412.7M; $527.4M unsettled forwards; >$1B available), so issuance has been accretive rather than dilutive — unlike most REITs that print stock below NAV (Fact/Interpretation). This only works while the premium multiple persists; it is a strength that inverts into a weakness on any de-rating.

Issuing shares to insiders? Yes, in the ordinary course: operator-incentive equity and $14.6M non-cash SBC in FY25 (Fact). Share count went ~66M (FY22–23) → 131M (FY24) → 166M (FY25), ~2.5x in three years — dominated by public capital raises, not insider grants, but SBC is a real ongoing non-cash cost added back in NFFO (Fact/Interpretation).

Director/management comp policy & motivations of management? Detailed proxy comp metrics were flagged as an Open question in the log (proxy comp targets and Form-4 insider detail not fully extracted — 173 Form 4s in the corpus but not itemized here) (Open question). What is known: management is internalized/self-managed (the external manager was folded in at formation in 2021), which aligns incentives better than the old non-traded external-management structure (Fact/Interpretation). Governance overhang: CEO Danny Prosky on medical leave since Feb 2026 (successful procedure ~Apr 2026, recovering, no reentry timeline); founder/Chairman Jeffrey T. Hanson is interim CEO/President — continuity via the founder, but a genuine key-person/succession risk until Prosky returns or a permanent plan is named (Fact).

Valuation & Market Data

Is the stock an ADR, MLP, or K-1 issuer? No — AHR is a US-domiciled REIT common stock (NYSE: AHR); it issues a 1099-DIV, not a K-1, and is not an MLP or ADR (Fact). One wrinkle: it owns UK/Isle of Man assets, so a portion of income is foreign-sourced (FX and foreign-tax considerations), but the security itself is an ordinary US REIT share (Fact/Interpretation).

Dividend policy? Conservative payout, low yield after the re-rating. Dividend ~$0.98/sh (2025), ~57% NFFO payout (room to grow), ~1.87% yield — low for a healthcare REIT because the ~4x price re-rating outran the distribution (Fact). Interpretation: the low yield means the stock is being owned for growth/total-return, not income — a very different (and more valuation-sensitive) buyer base than the typical REIT income investor, and a reason a de-rating could be sharp if growth disappoints.

How profitable is the business? See Business Quality — GAAP profitability is thin and only recently positive (FY25 +$70M); the meaningful profitability is NOI yield in the 7s, expanding NOI margins (Trilogy/SHOP ~20%+), and NFFO/sh growth (+20% guided for 2026) (Fact). Absolute operating margins are low (RIDEA), the trajectory is what the market is paying for.

Is net income diverging from cash from operations? Yes — materially, and by design for a REIT. GAAP net income to common was negative FY22–FY24 and only +$70M FY25, while CFO was $176M (FY24) and $294M (FY25) and NAREIT FFO was $293.3M FY25 (Fact). The wedge is overwhelmingly non-cash real-estate depreciation plus chronic impairments suppressing GAAP net income far below the actual cash the properties generate — the standard, legitimate REIT divergence (which is why FFO/AFFO exist) (Fact/Interpretation). The caution is the reverse case inside FFO: NFFO is flattered by a $23.7M non-cash tax benefit and other add-backs, so while GAAP << CFO is benign, NFFO should be trimmed for non-cash/one-time items before capitalizing (Interpretation).

Risks & Downside

What factors would cause the stock to decline?

• Multiple compression from richest-ever P/S (98.9th pct): the single biggest risk. At ~24.5x forward P/NFFO the stock is priced like WELL, well above the 12–18x where most healthcare-REIT peers trade — a re-rating toward peers, on nothing more than sentiment normalizing, is a large downside independent of fundamentals (Fact/Interpretation). This is the “richest-ever P/S” tell.
• Growth deceleration: SS NOI growth guided to step down (9–12% vs. trailing 12%+); when nine-quarters-of-double-digit normalizes to mid-single-digits, a growth-priced multiple compresses (Fact/Interpretation).
• Reimbursement: adverse CMS SNF rate action, MA plan rate pressure, or state Medicaid cuts hit Trilogy’s highest-margin book (Interpretation).
• Rate spike: the stock carries a negative InterestRate loading (-0.25) — long-duration, rate-sensitive; a back-up in real rates pressures both the multiple and the cost of the equity-funded growth engine (Fact).
• Reflexivity break: a de-rating raises the cost of equity, kills acquisition accretion, and slows external growth — a self-reinforcing down-loop that mirrors the up-loop (Interpretation).
• Key-person: unresolved CEO leave/succession (Fact).
• Cap-rate compression eroding buy-side spreads as capital returns (Fact).

Risk of a catastrophic loss? Low. AHR owns hard, below-replacement-cost real estate, is levered only ~3.0x net-debt/EBITDA (deliberately run toward IG), has a $0-drawn $800M revolver extended to 2030, and >$1B of available capital (Fact). It is not a going-concern or balance-sheet-fragility story. A catastrophic operating loss would require a simultaneous reimbursement collapse and occupancy reversal and a funding freeze — possible but not the base case (Interpretation).

Chance of a total loss? Very low. Diversified hard assets, modest leverage, and positive cash generation make a permanent total loss implausible short of fraud or an extreme systemic event (Interpretation). The realistic downside is not zero, it is a material equity de-rating — the stock is far more likely to lose a third of its value to multiple compression than to go to zero. Distinguish “permanent impairment of the business” (low) from “permanent impairment of this entry price” (a live risk) (Interpretation).

Recent News & Events

Has the business environment changed recently? Yes, on several fronts (Fact):

• IPO/listing Feb 2024 at $12 — AHR is a recently-listed former non-traded retail REIT, only ~2.4 years into public-market price discovery; the ~4x run and multiple re-rating are partly the market repricing a formerly-illiquid, externally-managed vehicle into a self-managed public comp of WELL/VTR (Fact/Interpretation).
• Trilogy consolidation: bought the remaining 24% for $258M (Q3’25), now 100% owner of the crown-jewel platform (Fact).
• CEO medical leave (Feb 2026) with founder Hanson as interim (Fact).
• Sell-side upgrades/initiations clustered in Jun–Jul 2026 (Citi, Barclays, UBS PT $63, Scotiabank) — sentiment turned uniformly bullish right at the all-time high (Fact); a crowded-long signal to weigh in Variant Perception.

Significant acquisitions? Yes — see Capital Allocation: Trilogy 24% buyout ($258M), ~$950M 2025 activity, $249.2M YTD SHOP acquisitions, $650M+ awarded pipeline (Fact).

Change in accounting policies? No wholesale policy change flagged, but the consolidation of Trilogy (from equity-method/JV to full consolidation) changes the comparability of the financials — post-buyout statements consolidate 100% of Trilogy revenue/NOI, inflating the top line and altering segment optics versus prior periods (Fact/Interpretation). Chronic impairment accounting continued FY22–FY25 (Fact).

Recent changes — new markets, facilities, management? New/expanding markets include Wisconsin and continued Trilogy campus expansions plus IL-villa developments; ongoing rotation out of Outpatient Medical (>1/3 sold) and triple-net, into SHOP/Trilogy operating senior housing (Fact). Management change: the Prosky leave / Hanson interim arrangement is the notable one (Fact). Portfolio spans 36 states + UK + Isle of Man, ~312 properties / ~19.0M sq ft (Fact).

Prepared as supplemental diligence to the AHR research memo. Fact/Interpretation/Assumption labels applied throughout. No recommendation or price target is expressed or implied in this appendix.

APPENDIX B — Source Appendix

American Healthcare REIT, Inc. (NYSE: AHR) — as of 2026-07-11

Primary sources first. Every non-obvious memo claim traces to an item below. Fact vs. Interpretation is labeled in the analysis.

1. SEC filings (primary — EDGAR CIK 0001632970)

• Form 10-K, FY2025 (filed 2026-02-27, ahr-20251231.htm) — audited financials; NAREIT FFO / Normalized FFO reconciliation; segment reporting (ISHC/Trilogy, SHOP, Outpatient Medical, Triple-Net); impairments; debt schedule; risk factors. Primary source for FY22–25 financials and FFO/NFFO.
• Form 10-Q, Q1 2026 (filed 2026-05-08, ahr-20260331.htm) — Q1’26 balance sheet, NFFO, segment NOI, net debt/EBITDA, ATM forward-sale disclosure.
• Form 10-K, FY2024 / FY2023 / FY2022 / FY2021 (ahr-20241231, ahr-20231231, ahr-20221231, gahr-20211231) — multi-year trend; pre- and post-listing history.
• Form 10-Q series FY2021–Q1 2026 (15 filings) — quarterly progression of occupancy, SS NOI, leverage.
• DEF 14A proxy (filed 2026-04-09, ahr-20260409.htm) — NEO compensation, incentive metrics, operator-incentive equity plan, board, insider ownership.
• Form 8-K series (~85 filings 2021–2026) — earnings releases (with supplemental packages), Trilogy 24% buyout, ATM/credit-facility events, CEO medical-leave / interim-CEO disclosure, board/management changes.
• Form 4 / Form 144 series (~173 Form 4s; multiple 144s incl. June 2026 cluster) — insider transaction record (open-market purchases vs. planned/10b5-1 sales and equity grants).
• S-11 / S-11-A, S-3ASR, S-4, 8-A12B — 2024 IPO registration and shelf/exchange-listing documents; predecessor merger (Griffin-American III + IV + American Healthcare Investors).

2. Management commentary (secondary — hypothesis, validated against filings)

• Q1 2026 earnings call transcript (2026-05-08; via ROIC.ai) — 2026 guidance raise ($2.09–$2.30 NFFO/sh), segment SS NOI detail, Trilogy CON/integrated-campus moat, MA quality-mix strategy, $650M acquisition pipeline, capital-sourcing philosophy, Prosky health update. Participants: J. Hanson (Interim CEO/Chairman), G. Willhite (COO), S. Oh (CIO), B. Peay (CFO).
• Prior-quarter earnings calls (via ROIC.ai list_earnings_calls).
• Company IR / investor supplemental packages — americanhealthcarereit.com.

3. Quantitative data services (third-party aggregated — reconciled to filings)

• ROIC.ai MCP (accessed 2026-07-11) — income statement, balance sheet, cash flow, enterprise value (~$10.4B), profitability/credit/liquidity ratios, company profile. Reconciled to 10-K/10-Q; filing is authoritative.
• AZI feeds (accessed 2026-07-11) — valuation_index own-history percentile ranks (P/S 98.9th pct = richest-ever; P/E and P/B percentiles disregarded per REIT/garbled-book caveats); news feed (sell-side rating actions).
• FactorsToday (accessed 2026-07-11) — factor loadings (Real Estate/Market/REITs/LowVol/Momentum positive; Quality/InterestRate negative), leaderboard (y1 +51.1%, Sharpe 2.02, max DD −13.6%), stock-info (beta 0.46, alpha +0.77), related stocks.
• AZI price CSV (accessed 2026-07-11) — split/dividend-adjusted OHLCV history since IPO; five-year event-map price levels.

4. Third-party / sell-side references (color only, not evidence)

• Citigroup (upgrade to Buy, 2026-06-23); Barclays (initiate Overweight, 2026-07-07); UBS (Buy, PT $63, 2026-07-08); Scotiabank (Sector Outperform, 2026-06-18) — via AZI news feed. Cited as consensus positioning, not as valuation authority.

5. Peer / cross-read (prior published analysis)

• output/WELL_2026-06-12_full_report.md (Welltower) — premium SHOP comp.
• output/VTR_2026-06-26_full_report.md (Ventas); output/DOC_2026-07-11_full_report.md (Healthpeak) — healthcare-REIT industry structure and comps.

6. Analytical frameworks

• investment-research-frameworks skill — Greenwald & Kahn (Competition Demystified): moat taxonomy, CON captivity, local-scale advantage. Marathon (Capital Returns): supply-side capital-cycle read of senior housing.